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Abstract 
Objective Mycobacterium bovis BCG is used as a live vaccine against tuberculosis. RecA-dependent homolo-
gous recombination is a major driving force of bacterial evolution (1). Therefore a RecA phenotype is recom-
mended for all live vaccines (2-4). RecA- life vaccines demonstrate increased genetic stability and are favourable 
because of a reduced risk of reversion to virulence. Characterization of marked recA mutants provided proof of 
principle that persistence in the host, which is a major criterion of vaccine efficiency, is not affected by the dele-
tion of recA (5). However, due to the presence of antibiotic resistance markers such a recombinant strain may not 
be used in human vaccination trials (6). The aim of this study was to generate unmarked recA deletion mutants in 
phylogenetically different Mycobacterium bovis BCG substrains.  
Methods Six BCG vaccine substrains were selected based on the following criteria: The substrains had to fea-
ture a complete historical documentation with date of lyophilization for the primary seed lot, protective effi-
ciency in case control studies, an official WHO, FDA or government issued permission for human use, and a 
molecular description (regions of difference, and single nucleotide polymorphisms in comparison to M. bovis 
AF2122/97). Identity of the substrains was confirmed by molecular techniques. Mixed cultures with more than 
one genotype were excluded. Unmarked inactivation of recA was achieved with a suicide (i.e. non-replicative) 
knock-out plasmid containing a partially deleted recA allele flanked by a hygromycin and a kanamycin select-
able marker and a levansucrase (sacB) counterselectable marker. SacB induces sucrose sensitivity in mycobacte-
ria and allows the isolation of allelic exchange mutants in a two-step selective process (7). M. tuberculosis 
H37Rv recA was cloned into the suicide vector together with approximately 1.2 kbs of flanking genomic DNA. 
The genomic sequences of the cloned region are identical in M. bovis AF2122/97 and M. tuberculosis H37Rv. 
An in-frame stop codon (following amino acid residue 169) was introduced in the cloned recA instead of an 
internal 1.2-kb PstI fragment. BCG substrains were grown in Middlebrook media; electrocompetent cells were 
produced and transformed with the suicide knock-out plasmid. Following selection of single-crossover transfor-
mants at the recA locus on hygromycin B containing media, deletion mutants resulting from intramolecular re-
combination were isolated after a counterselective step on 10% sucrose containing media. The respective geno-
types were determined by PCR and Southern blot analyses. 
Results Unmarked recA deletion mutants were obtained in BCG substrains Frappier, Pasteur, and Denmark. In 
BCG Tice and BCG Phipps, single-crossover mutants for the recA locus could be isolated. After counterselec-
tion, only reversion to wild-type allele or persistence of the single-crossover genotype was noted. In BCG Russia 
only illegitimate recombinant mutants were obtained. Illegitimate integration excludes generation of recA dele-
tion mutants as an intramolecular recombination does not occur. Sequencing of the recA locus revealed a mecha-
nistic explanation for the inability to obtain homologous recombination in BCG Russia. This substrain has an 
insertional single nucleotide polymorphism (SNP) in recA causing translational frame shift and truncation of 
RecA. Thus, tuberculosis vaccine strain BCG Russia is a natural recA mutant. 
Conclusion The presented strategy allows generation of unmarked allelic exchange mutants for the recA locus in 
M. bovis BCG and delivered new recA- vaccine candidate strains that base on three well-documented BCG vac-
cine substrains. The mutants are free of genomic selectable and counterselectable markers. The constructed sui-
cide vector backbone for the generation of unmarked allelic exchange mutants may be used for other allelic 
exchange experiments in mycobacteria. BCG Russia recA SNP provides an explanation for the observed high 
degree of in vitro evolutional stasis.  
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Outlook The deletion of recA in M. bovis BCG leads to a stable genome in this live vaccine reducing the risk of 
further attenuation or reversion of virulence in the process of vaccine production and in vaccinees. The availabil-
ity of recA mutants in M. bovis BCG substrains facilitates the construction of heterologous antigen expression 
vectors for the intracellular compartment with stable expression of recombinant antigens profiting from BCG’s 
long generation time and persistence in the host. 
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1 Introduction 
1.1 Global impact of tuberculosis 
The global burden of tuberculosis infection is a matter of growing concern to the WHO and UNAIDS 
(8). The 2005 estimates according to the WHO fact sheet on tuberculosis (9) predict that one third of the total 
global population is chronically infected with Mycobacterium tuberculosis and nearly 9 million people were 
newly infected in 2005. Mortality due to this disease is devastating, with estimated 1.6 million deaths annually 
(including those of HIV-infected individuals). 
In addition to rising epidemiological concerns on the spread of M. tuberculosis (10), there is a new 
threat to the global health: An increasing number of clinical strains showing resistance towards at least rifam-
picin and isoniacid have been isolated in the last few years. These strains fulfil the definition of multi-drug resis-
tant tuberculosis and the treatment of these infections requires expensive second-line antibiotics and is often 
condemned to failure (11-13). Estimates are that more than 4% of all patients with tuberculosis worldwide have 
an infection with a multi-drug resistant strain (14). Even more concerning strains that are described as exten-
sively drug resistant (XDR), are on the rise. XDR strains are defined as being resistant to fluoroquinolones and 
one or more of three injectable second-line drugs (capreomycin, kanamycin and amikacin) in addition to the 
previously mentioned first-line antibiotics (isoniazid and rifampicin). XDR tuberculosis cases have been found 
in at least 17 countries on all continents (15). 
 
 
Figure 1. Worldwide incidence of tuberculosis in 2005. Source: WHO (16). 
 
The role of vaccination in the prevention of tuberculosis is a field of ongoing debate and research: Since 
1997, Ian Orme, David McMurray et al. have tested over 170 vaccine candidate strains in a NIH-funded program 
(17, 18). Even though four different concepts of vaccination strategies (subunit vaccines, DNA vaccines, live 
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attenuated mycobacteria and non mycobacterial-antigen delivery systems) were pursued, so far only the strategy 
of a standard intracutaneous BCG vaccination followed by protein antigen boost has proofed better protective 
efficacy in a guinea pig and mouse TB aerosol exposure model than the current Danish BCG vaccination strain 
that is recommended by the WHO (10). 
 
Table 1. Novel vaccines against human tuberculosis, based on (10). 
Name Type Effectivness evidence Developmental state References 
Modified vaccinia Ankara 85A Live attenuated vector Mice, guineapigs Phase II  (19-22) 
72f fusion protein Subunit Mice, guineapigs, macaques Phase I  (23) 
rBCG30 Recombinant BCG Guineapigs Phase I  (24-26) 
ESAT6-85B fusion Subunit Guineapigs, macaques Phase I  (27) 
ESAT6-TB10.4 fusion Subunit Mice Preclinical (28) 
ΔureC hly+ rBCG Attenuated recombinant BCG Mice Preclinical (29, 30) 
ΔrecA rBCG Recombinant BCG Mice Preclinical (5, 31) 
 
1.2 The BCG vaccine 
The live attenuated strain of Mycobacterium bovis, which was developed by Albert Calmette and Camille 
Guérin between 1906 and 1919 at the Institut Pasteur at Lille and named thereafter, M. bovis BCG, is the 
world’s most used vaccine. More than three billion doses have been administered in the vaccine’s 85 year his-
tory (32). It is the only anti-tuberculosis vaccine that is in use on large scale and has a WHO approval. BCG was 
generated from a virulent isolate of M. bovis from a heifer with mastitis, which was collected by Nocard. The 
strain that was eventually to become BCG was sub-cultured every three weeks from 1908 to 1918, a total of 230 
continuous passages on potato slices soaked in ox bile and glycerol. During in vitro cultivation genetic altera-
tions accumulated, resulting in loss of virulence factors and therefore attenuation occurred. After this in-vitro 
attenuation, Calmette and Guérin demonstrated stable attenuation in several laboratory animals and cattle. The 
new vaccine was first used in a human newborn on July 18, 1921 by Weil-Halle, a colleague of Calmette and 
Guérin in France (33, 34). The baby was at risk to develop tuberculosis and eventually die of tuberculosis be-
cause of contact to infected housemates. Starting in 1924 worldwide use and rapid global distribution of primary 
seed lots was noted. Scepticism concerning the safety and efficacy of BCG vaccine, and the Lübeck incident in 
which 72 of 240 children vaccinated with BCG died as a result of a vaccine batch contamination with virulent 
M. tuberculosis which was cultured in the same incubator as the vaccine (35), delayed the acceptance of BCG. A 
series of controlled trials begun in the 1930s (36). Despite inconsistent results from the trials, WHO encouraged 
widespread dissemination of BCG vaccines, starting in the 1950s (37). Since 1924, many different laboratories 
have maintained BCG, using different culture methods. As a result, the BCG substrains used today are not iden-
tical. The bacilli resulting from the original attenuation have never been cloned. The original strain of BCG has 
been lost and has been replaced by a variant while being serially transferred on artificial culture media at the 
Pasteur Institute (38). Both phenotypic and genotypic differences between substrains have been described (39-
41). Since BCG substrains vary in protein expression, lipid composition, and behaviour in laboratory animal 
models and humans, an evidence of genetic instability has been supposed (42). Thus the term BCG does not 
describe a genetic entity but refers to a heterogeneous set of substrains. The BCG vaccine family has undergone 
major genetic rearrangements resulting in deletion and duplication of segments of its chromosome. More than 
INTRODUCTION 
   3
129 open reading frames clustered in 16 regions of difference (RD) are absent from the genome of BCG sub-
strain Pasteur as compared to the M. tuberculosis reference strain H37Rv (43). 
There is general agreement that the vaccine is effective against the disseminated forms, miliary tubercu-
losis and tuberculous meningitis in children (32) but the protective efficacy for BCG vaccines against adult pul-
monary tuberculosis ranges between 0% in the Southern United States and Chingleput, Southern India versus 
80% in the United Kingdom. Protection varies with geographic region, exposure to environmental mycobacteria, 
nutritional status, intensity of infecting dose, differences in the infectivity of M. tuberculosis strains, genetic 
differences in the population, methodological study design, and vaccine strain variations (44-46). The debate 
continues on how to interpret the results of the meta-analysis of the published field-trials and on the effective-
ness of today’s BCG vaccinations (47). Reliable correlates of protection should be established with respect to 
novel improved BCG-based vaccine candidates (Table 1). 
1.3 RecA function and structure 
1.3.1 Relevance of recA in genetic stability of vaccine strains 
Genetic alterations may effect attenuation of life vaccines, making them either more harmful to the host 
and contacts or overattenuate vaccines and thereby lower the protective efficacy (48). The history of BCG shows 
only rare major adverse effects in the world’s most used vaccine. Genetic alterations have never led to a rever-
sion to the level of pathogenicity noted with wild-type M. bovis. Most of the observed adverse effects were due 
to immunological disabilities in the vaccinated or wrong application technique (intramuscular injection instead 
of intracutaneous injection). The estimated case fatality in the process of vaccination is very low (0.19 per mil-
lion). Therefore BCG is among the safest vaccines. Unfortunately, a decrease of protective efficacy was noted 
over the years of application. This could either mean that the process of attenuation, which was induced by Cal-
mette and Guérin through culture conditions to isolate the vaccine, was still ongoing or that the natural pathogen 
M. tuberculosis was evolving and changing its immunological behaviour in a way that escaped protection in 
vaccinated individuals. Because protection was decreasing with higher passage number of vaccine strains, an 
ongoing genetic evolution of the vaccine strains was supposed (42). Freeze-drying (lyophilization), which was 
introduced in the late 1950s, slowed down in vitro evolution as it eliminated the necessity of continuous subcul-
tivation. In 1966, the WHO Expert Committee on Biological Standardisation adopted a series of recommenda-
tions for the production of BCG vaccine (49). These recommendations stated that the vaccine should be freeze-
dried, and that the vaccine strain should be maintained by a seed-lot system whereby the number of passages of 
the vaccine lot should not exceed twelve passages. Most laboratories soon adopted this method of maintenance 
and it decreased the likelihood of selecting variants in later BCG vaccine lots. An expert committee recently 
reviewed the recommendations and now states not to exceed even lower passage counts from a primary lot (50). 
Ho et al. recommended PCR assays to monitor genetic alterations in vaccine production (51).  
In M. bovis BCG – as in enteric bacteria – RecA is a key element of homologous recombination and a 
central regulator of the error prone DNA repair mechanism (SOS response). The synthesis of the RecA protein is 
inducible by DNA damage and RecA initiates the SOS response by forming filaments at the site of DNA dam-
age. It facilitates autocatalytic cleavage of the SOS-repressor protein LexA (52). A deletion of recA leads to 
attenuation of some intracellular pathogens. E.g. in Salmonella typhimurium, deleterious mutations of recA have 
little effect on in vitro growth but significantly attenuate virulence in susceptible mice (53). In contrast BCG 
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recA mutants show a wild-type persistence in a mouse TB challenge model (5). In general, live vaccines should 
possess a recA- phenotype. recA- mutant strains are genetically more stable than their recA+ counterparts, reduc-
ing concerns about major genetic changes and rearrangements resulting in an altered phenotype (2). Even though 
RecA acts as an inducible positive regulator of interspecies gene exchange in general (54), mycobacteria exhibit 
strong barriers to this mechanism. None the less a mutant recA allele averts reversion of virulence attenuation by 
interspecies gene transfer (e.g. with M. tuberculosis). Mycobacteria lack a classical mismatch repair system (55). 
Variation due to single nucleotide polymorphisms is exceptionally rare (56) and only minimally accounts for 
genome evolution. Genomic evolution happens either through insertion sequence (IS) triggered events, slipped-
strand mispairing during replication, or recombination leaving a patched genome with insertions, deletions and 
gene duplications (57, 58). For instance, M. bovis BCG substrain Pasteur 1173-P2 has been analyzed by Brosch 
et al. (59). They found a 29-kb tandem duplication (DU1) in its genome, compromising the origin of chromo-
some replication oriC and another duplication of 36 kbs (DU2) corresponding to sequence positions between 3 
590 900 and 3 690 124 in M. tuberculosis H37Rv (after occurrence of an internal deletion of 63 kbs, Δint). These 
two major rearrangement in the genome of this reference vaccine strain can be assigned to recombination of 
short DNA homologies which might have occurred as a result of RecA activity as outlined by Edlund et al. for E. 
coli RecA activity (60). A recA knock-out mutation in BCG reduces further genomic evolution to rare point 
mutations and IS triggered events. Even though mutant recA- strains are more sensitive to DNA damaging agents 
such as UV-light and alkalylating substances, ΔrecA BCG strains exhibit wild-type persistence and protection in 
a mouse vaccination model (5, 31).  
1.3.2 Structure of mycobacterial recA genes 
There is a major difference between the recA locus of Mycobacterium tuberculosis and its paradigmati-
cal E. coli homologue. The recA gene in the pathogenic mycobacteria M. tuberculosis, M. bovis and M. leprae 
contains an in-frame insertion sequence which has no homology to the recA sequences found in other bacteria 
(61). The mentioned intervening sequence was termed intein. It is transcribed and translated as a part of RecA 
but spliced out posttranslationally (62). The intein is absent in Mycobacterium smegmatis (63). The intervening 
sequence harbours an open reading frame that encodes for a Mn2+-ATP-dependent double strand specific endo-
nuclease PI-MtuI (64, 65). In the spectrum of the genetically analysed human pathogenic bacteria, inteins are 
unique to mycobacteria.  
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Figure 2. Organization of the recA locus in M. tuberculosis/M. bovis (A) and M. smegmatis (B). In all three organisms, recA is cotranscribed 
with recX, which encodes for a putative regulatory protein. In contrast to M. tuberculosis and M. bovis, recA of M. smegmatis does not 
contain an intein (protein-splicing element). The two promoters upstream of recA are indicated with P1 and P2 (more distal from start codon 
of recA than P1). 
 
In mycobacteria, the sequence encoding for recA lies on the complementary strand. In M. tuberculosis 
and M. bovis, the recA genes share 100% sequence identity. In M. tuberculosis, M. bovis, M. leprae, and M. 
smegmatis recA is cotranscribed with recX, a potential regulator of recA. The recX open reading frame overlaps 
recA, which makes the mycobacterial recA locus unusual. Although recX appears in many bacterial species, it 
rarely forms a recA-recX operon as in the mentioned mycobacteria. In M. tuberculosis and M. bovis, this operon 
is expressed from two promoters termed P1 and P2 upstream of recA, including a promoter with a LexA binding 
site. The two transcription start sites for recA have been identified by primer extension (66). One of the promot-
ers, P1, is DNA damage inducible independently of LexA and RecA while the other, P2, is regulated by LexA in 
the classical way (67); i.e. the transcription of recA is repressed by the binding of LexA to an SOS box and is 
inducible by DNA damage as in other bacteria. The binding site for LexA is located between the putative -10 
and -35 sequences for P2. The P1 promoter sequence are similar to the -10 and -35 sequences in E. coli σ70 (68). 
 
1.3.3 Structure and function of mycobacterial RecA protein 
In M. bovis (as in M. tuberculosis) two important proteins of DNA repair and homologous recombina-
tion RecA and DnaB, are interrupted by inteins that must be excised by protein splicing before the translation 
products are functional (69). Overall the structure of spliced M. tuberculosis MtRecA is very similar to E. coli 
EcRecA, consistent with a high amino acid sequence similarity of 62% over the 352 amino acid polypeptide 
chain of the mature MtRecA (70). The active 38 kDa form of MtRecA with 352 amino acid residues develops 
after splicing of the intein region from an 85 kDa inactive precursor protein (61). The splicing site at amino acid 
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residues 253 and 254 (numbering refers to mature form) lies in the major central M domain of the active protein 
and is well conserved in comparison to other species with the exception of Cys252 that forms an ester intermedi-
ate with Cys253 by nucleophilic attack of the sulfhydryl group thereby starting the splicing process (71). The 
MtRecA protein features three domains; a 30 amino acid residue N-terminal domain consisting of a long α-helix 
followed by the M domain (amino acids 31-269) which is followed by a 59 amino acid residue C-terminal do-
main. The M domain, which is made up of twisted eight stranded β-sheets flanked by four α-helixes, harbours 
all features that are vital for the function of the RecA protein: a P-loop contains a triphosphate hydrolase fold, 
and two loops L1 and L2 are implicated in the binding of single-stranded DNA (ssDNA).  
MtRecA display the hallmarks of EcRecA domains used to promote homologous recombination as out-
lined by the Holliday (72, 73) and subsequent models: binding to single-stranded DNA, ssDNA dependent ATP 
hydrolysis, formation of D-loops, homologous pairing of single-stranded DNA with duplex DNA, and strand 
exchange can be demonstrated for MtRecA (74). However, there are striking differences to EcRecA in the 
slower rate of ATP-hydrolysis by MtRecA and cofactor-dependence like the single strand binding protein (SSB) 
that is absolutely needed for the process in the case of MtRecA and other mycobacterial RecA proteins (75). In 
contrast to the RecA protein of M. smegmatis which has a maximal efficiency for strand exchange at neutral pH, 
MtRecA shows maximal efficiency of strand exchange in the alkaline pH range (76). Early gene disruption stud-
ies with short (77) and long (78) linear DNA fragments and suicide plasmids (79) suggested that the recombina-
tion machinery in M. tuberculosis and M. bovis in general is inefficient and prone to illegitimate recombination. 
However, more detailed investigations demonstrate that M. tuberculosis is proficient for homologous recombina-
tion (63, 76). In M. tuberculosis, an unusually long lag period has been observed in the appearance of RecA after 
DNA damage. Western blot analysis of the apparent RecA protein before and after induction of DNA damage 
has demonstrated only mature (i.e. spliced) RecA protein thereby suggesting that the splicing process is not rate 
limiting in expression of functional RecA (80). Splicing of MtRecA has been achieved in a heterologous expres-
sion system, and expression of the M. tuberculosis recA locus can complement M. smegmatis recA for homolo-
gous recombination and DNA repair (63).  
 
1.3.4 Strategies for the generation of a gene knock-out in mycobacteria 
The first report on allelic exchange in mycobacteria was a pyrF::aph mutant of M. smegmatis for which 
the target gene was inactivated by introduction of a suicide plasmid and subsequent selection for the mutant 
strain based on the kanamycin resistance of single- and double-crossover mutants (81). This strategy has proved 
useful for other loci in M. smegmatis, M. tuberculosis, and M. bovis (including BCG). Actually, a recA deletion 
mutant in BCG was generated using this strategy too (5). The introduction of an antibiotic resistance marker is 
unpreferable in life vaccines (6). Early attempts to achieve gene knock-outs in M. tuberculosis and M. bovis 
BCG were based on linear DNA fragments carrying the inactivated allele. The idea behind this delivery system 
was to increase recombinogenicity of the invading DNA and hence facilitate the recovery of allelic exchange 
mutants. The respective studies met large difficulties, which were attributed to peculiarities of slow growing 
mycobacteria, particularly their RecA. Many of the isolated mutants incorporated the invading fragments by 
illegitimate recombination. A leuD auxotrophic mutant could be isolated using very large stretches of homolo-
gous genomic DNA flanking the allele to be deleted. Because the recA loci of M. tuberculosis and M. bovis con-
tain an intein there were speculations that these species were defective in homologous recombination (77). In the 
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following years, several workgroups demonstrated that homologous recombination is readily achievable in M. 
tuberculosis. The irrelevance of the intein with respect to RecA function was finally revealed and confirmed by 
Frischkorn et al. in 1998 (82) and Papavinasasundaram et al. 1998 (63). The next major advance came with easy 
usable selectable and counterselectable markers. Single gene knock-out by homologous recombination involves 
crossover events on either side of the desired mutation; mutant identification is simplified by availability of 
methods to distinguish allelic exchange (double-crossover) from partial merodiploid products of a single-
crossover event and from the background resistant mutants. Two step strategies using positive i.e. kanamycin 
resistance (aph) and negative selection i.e. streptomycin sensitivity (rpsL) enabeled knock-out generation in slow 
growing mycobacteria to so far unachieved values. Another two step strategy was described by Pelicic et al. 
(83): A suicide vector construct with an inactivated target allele, flanked by kanamycin and/or hygromycin resis-
tance cassettes as selectable markers, and a sucrose sensitivity conferring cassette (sacB levansucrase encoding 
gene from Bacillus subtilis) as counterselectable marker. This strategy results in truly isogenic strains that only 
differ in the target gene and it does not leave any marker-scar in the mycobacterial genome after a knock-out 
generation procedure. The incorporation of two positive selectable markers allows choosing the marker in the 
process of generating the respective mutant according to the performance of the selection. The B. subtilis levan-
sucrase was already examined in 1966 by Dedonder (84). In B. subtilis, levansucrase (sucrose: 2,6-β-D-fructan 
6-β-D-fructosyltransferase; EC 2.4.1.10) is a secreted enzyme that catalyzes hydrolysis of sucrose and synthesis 
of levans (high-molecular-weight fructose polymers). The sacB gene was first used successfully as a counterse-
lective marker for the generation of unmarked mutations in Escherichia coli, Erwinia chrysanthemi, and Le-
gionella pneumophila, demonstrating that expression of sacB in the presence of sucrose is lethal in gram-
negative bacteria (85-87). Later on, expression of sacB in the gram-positive Corynebacterium glutamicum 
showed a cytotoxic effect in presence of sucrose (88). Investigation of sacB expression in mycobacteria revealed 
that it has a toxic effect on cells of M. smegmatis, M. bovis BCG and M. tuberculosis at 2% (in the fast growing 
species) respectively at 10% (in the slow-growing) sucrose concentration in the culture medium making it a 
useful tool for counterselective procedures in mycobacteria too (7, 89). There are several hypothesises explain-
ing the molecular basis of levansucrase toxicity in hosts other than B. subtilis. In gram-negative bacteria the 
toxicity might be due to accumulation of levans, which bulk the periplasm due to their high molecular weight or 
due to transfer of fructose residues to inappropriate acceptor molecules thereby compromising the function of 
certain metabolic pathways. Because the gram-positive C. glutamicum owns a membrane-like outer structure 
mostly consisting of mycolic acids, lethality was suggested to correlate with the gram-negative model. The lethal 
effect in mycobacteria may be explained in the same way. 
Other strategies for the generation of unmarked mutations in mycobacteria like specialized transduction, 
which allows the generation of unmarked mutants as well, are valuable alternatives for the strategy exploited in 
this study. 
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1.4 Aims of the study 
1) Selection and characterisation of representative M. bovis BCG vaccine substrains that have 
(a) a continuing historical documentation with respect to passage number, morphological 
features, date of lyophilization, and protective efficacy in case control studies. The BCG 
substrains to be selected (b) should have a WHO, FDA or government issued approval for 
human use.  
2) Cloning of a recA targeting vector: The primary goal of the study is to generate unmarked 
recA gene knock-out mutants; i.e. inactivating recA without leaving a residual antibiotic re-
sistance or auxotrophic selectable or counterselectable marker after the genetic manipulation 
in well characterized vaccine substrains.  
3) Transformation of BCG substrains with targeting vector: Culture conditions should repre-
sent little selective pressure towards certain phenotypes and the passage count to generate 
the knock-out mutants should be as low as possibly attainable to prevent further genetic re-
arrangements. 
4) Identification of recA single-crossover intermediates.  
5) Counterselection of recA single-crossover transformants. 
6) Identification and characterization of unmarked recA mutants. 
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2 Material and Methods 
2.1 Bacterial strains 
2.1.1 Mycobacterium bovis BCG vaccine strains 
The following strains were selected for the knock-out generation: 
 
M. bovis BCG, substrain Pasteur (1173P2-B), dated 1961, CIP # 105050, TMC 1011, further descriptor 
1117 on vial), obtained through Institut Pasteur, Paris, France. This strain is the current vaccine strain as referred 
by the Institut Pasteur and has been sequenced recently (41). It has the broadest documentation (passage number, 
lyophilization date) and was widely used in large field trials (46). It was derived in 1961 from single colony out 
of 30 colonies examined that yielded cultures, which corresponded – mostly in terms of pigmentations – to the 
original description of culture morphology by Calmette. This specific CFU was selected for freeze-drying, 
termed 1173P and the second batch is now the primary seed lot of BCG ‘Paris’ or ‘French’. Recent studies have 
shown that this particular substrain underwent two major rearrangements with tandem duplications in the ge-
nome with respect to the M. bovis AF2122/97 sequence (41, 59).  
 
M. bovis BCG, substrain Tice (Chicago), OncoTICE®, dated 1973, lot 177415, exp. date. 2005-05-24, 
obtained through Organon Ltd, Seattle, USA. The Tice substrain was developed at the University Illinois, Chi-
cago, IL, USA (S. Rosenthal, R. Dubos, and A. Jespersen): In 1933 Dr. Rosenthal was sent to Paris by Dr. Tice 
to obtain a seed-lot of BCG and learn vaccine production techniques. The substrain he received later became 
known as BCG Tice-Rosenthal and is called BCG Tice today. Rosenthal cultured at least six substrains (H, K, E, 
L, LH, and BL) derived from the initial strain during cultivation in the U.S.; all of these were used for vaccine 
production. In October 1952, Rosenthal mixed three culture flasks of the BL variant with one flask of the new 
standard strain obtained from Institut Pasteur in 1951. This mixed culture was called BLP. It was lyophilized in 
1952 and since then only batches originating from this lot have been used for vaccine production (90). Behr et al. 
described only one pattern of genomic deletions in the Tice substrain (91). Horwitz et al. used BCG Tice for the 
generation of a recombinant M. bovis BCG vaccine which expresses a M. tuberculosis 30-kDa major secretory 
protein (25). The unmodified strain has shown a slight tendency towards higher protective efficacy and tubercu-
lin conversion rate in recent trials (48). BCG Tice has an FDA approval (92) as a antineoplastic agent in the 
treatment of primary or relapsing flat urothelial cell carcinoma in situ (Tis) of the urinary bladder, and as an 
adjuvant therapy after transurethral resection (TUR) of a primary bladder tumor or relapsing superficial urothe-
lial cell carcinoma of the bladder stage Ta (the cancer is just in the innermost layer of the bladder lining; grade 1, 
2 or 3) or T1 (the cancer has started to grow into the connective tissue beneath the bladder lining; grade 1, 2, or 
3). 
 
M. bovis BCG, substrain Frappier (Montreal), primary lot, dated 1973, lot number 1376141, obtained 
through the American Type Culture Collection (ATCC # 35735), Rockville, MD, USA. The Frappier strain held 
by ATCC was initially transferred from the Institut Pasteur to Frappier’s Institute in Montreal in 1937, was inte-
grated in the Trudeau Mycobacterial Culture Collection and finally went to the ATCC. This strain showed per-
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sistently high protective efficacy even after high passage numbers (48). It was used in the large Saskatchewan 
field trial in 1933 (93), where it showed a protective efficacy of 82% in a follow-up period of 15 years. These 
data were extensively peer-reviewed (44, 94) and another follow-up study (95) confirmed this efficacy data.  
 
M. bovis BCG, substrain Russia (Moscow), ATCC # 35740, dated 1924, vial from Medgamal 
(Медгамал), descriptor “Vakzina tuberkueznja (BCG) suchaja”, in Cyrillic letters: Вакцина Туберкуленая 
(БЦЖ) сухая, lot number S. 547-1104 K. 1491, exp. date 12.2006, obtained through Torgovyi Dom Allergen 
(Allergen Trading House), Moscow, Russia. This was the first documented daughter strain distributed by Institut 
Pasteur in 1924 (96) going directly to Russia. It is referred as an ‘early strain’ (43) in regard to its genetic charac-
teristics (RDs, insertional elements, antigen expression pattern). 
 
M. bovis BCG, substrain Denmark (1331, Glaxo®, Mérieux®), obtained through the Statens Serum In-
stitute, Copenhagen, Denmark. This substrain is nowadays accredited in the states of the European Union as 
official BCG vaccine. Several commercial producers offer this substrain in vaccine vials (Aventis, BioMérieux). 
Vaccine containing this substrain is WHO pre-qualified for sale to UN agencies including UNICEF (97). Ac-
cording to Oettinger et al. (90) Statens Serum Institut was provided with a BCG lot by Calmette in 1927. This 
first Danish substrain was believed to be to reactogenic and in November 1931, another BCG strain (transfer 
423) was obtained from Institut Pasteur. In 1960 batch 1331 was freeze-dried and became the primary seed-lot of 
BCG Denmark (90). 
 
M. bovis BCG, substrain Phipps (Philadelphia), ATCC # 35744, dated 1928, vial dated Jan. 9.87, ob-
tained through the American Type Culture Collection, Rockville, MD, USA where it arrived from Institut Pas-
teur, via J. Aronson, A. Dannenberg, Jr. and the Trudeau Mycobacterial Culture Collection. It has shown only a 
slight decrease in protective efficacy in trials with increasing passage numbers (48). 
 
Even though the M. bovis BCG, substrain Japan is prequalified for sale to UN agencies and in large 
use, we didn’t implement the Japan substrain, which is also referred as Tokyo 172, because molecular compari-
sons of the current Japan vaccine substrain and asservational samples from ATCC have shown that this substrain 
owns more than one molecular type (IS6110 -2/mpt64+ and IS6110 -1/mpt64-) (43). The current vaccine strain is 
described as mixed culture of two subpopulations differing in RD16 regions (98). As we intended to generate a 
clone, the presence of more than one genotype is undesirable.  
 
All vaccine strains were delivered in freeze-dried state and revitalized according to the prescriptions of 
the delivering manufacturer (see 2.2.3.2).  
 
2.1.2 Escherichia coli strains 
E. coli XL1-Blue MRF´, Genotype: Δ(mcrA)183, Δ(mcrCB-hsdSMR-mrr)173, endA1, supE44, thi-1, 
recA1, gyrA96, relA1, lac [F´ proAB lacIqZΔM15Tn10 (Tetr)]. XL1-Blue MRF´ cells are tetracycline resistant. 
The XL1-Blue MRF´ (Minus Restriction) strain is a restriction minus (McrA–, McrCB–, McrF–, Mrr–, HsdR–) 
derivative of Stratagene’s XL1-Blue strain. XL1-Blue MRF´ cells are deficient in all known restriction systems 
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[Δ(mcrA)183, Δ(mcrCB-hsdSMR-mrr)173], and are endonuclease (endA), and recombination (recA) deficient. 
The hsdR mutation prevents the cleavage of cloned DNA by the EcoK endonuclease system, and the recA muta-
tion helps ensure insert stability. The endA1 mutation improves the quality of miniprep DNA. XL1-Blue MRF´ 
cells contain the lacIqZΔM15 gene on the F´ episome, allowing blue/white screening for recombinant plasmids. 
The XL1-Blue strain was used as standard plasmid construction vehicle in this study unless otherwise indicated. 
The cells were obtained from Stratagene, La Jolla, CA, USA. 
 
E. coli DH5α , Genotype: F-, φ80ΔlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rk-, 
mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1. This strain shows high insert stability due to its relA1 mutation. It 
can be used for blue/white screening and tolerates large plasmids due to its deoR mutation. High plasmid yield 
can be obtained due to an endA1 mutation. This strain was originally used for chemo-competent cells but has a 
high transformation efficiency being used in a protocol for electro-competent cells too (99). Because an XbaI 
digestion of a plasmid preparation from this strain is possible, Dam-dependent methylation is considered to be 
absent in this strain. It was used for plasmid propagation with subsequent Dam susceptible restriction endonucle-
ase digestion. This strain was initially obtained through Invitrogen, Bale, Switzerland and the methylation defi-
cient mutant strain was obtained from Maria Magdalena Senn (unpublished). 
 
2.2 Culture techniques 
2.2.1 Growth media 
LB (Luria Bertani) liquid medium: - Bacto™ Yeast extract (BD, Sparks, MD, USA), 5 g 
 - Bacto™ Tryptone (BD), 10 g 
 - NaCl, 10 g 
 - Distilled water ad 1000 mL, adjustment of pH to 7.5 with  
     4 % NaOH 
 
LB agar medium:  - LB medium, 1000 mL 
 - Granulated agar (Difco, Bale, Switzerland), 15 g 
 
Middlebrook 7H9 OADC: - Middlebrook 7H9 (Difco), 4.7 g 
 - Glycerol (Sigma, Buchs, Switzerland), 2 mL 
 - BBL™ Middlebrook OADC enrichment (BD), 100 mL 
 - 10% Tween-80, 5 mL 
 - Distilled water, ad 1000 mL 
 
Middlebrook 7H10 OADC agar medium: - Middlebrook 7H10 agar base (Difco), 19 g 
 - Glycerol (Sigma), 5 mL 
 - BBL™ Middlebrook OADC enrichment (BD), 100 mL 
 - Distilled water, ad 1000 mL 
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Middlebrook 7H10 OADC, 2 %/5%/10% sucrose 
agar media: - Middlebrook 7H10 agar base (Difco), 19 g 
- Glycerol (Sigma), 5 mL 
- BBL™ Middlebrook OADC enrichment (BD), 100 mL 
 - 20 g (2%)/50 g (5%)/100 g (10%) cell media tested  
    sucrose (Roth, Reinach, Switzerland) 
 - Distilled water, ad 1000 mL 
 
 
CDC 5% Sheep blood agar: - Pancreatic Digest of Casein (BD), 15 g 
 - Sodium Chloride (Sigma), 20 g 
 - Granulated agar (Difco), 20 g 
 - Yeast Extract (BD), 5 g 
 - Hemin (BD), 0.0005 g 
 - Vitamin K1 (from pharmacy), 0.01 g 
 - L-Cysteine (Sigma), 0.4 g 
 - Sheep blood, defibrinated (BD), 5% 
 - Distilled water, ad 1000 mL 
 
All media were autoclaved. OADC enrichment was added under a laminar flow hood after the auto-
claved media had cooled down to a temperature of 50 °C. When needed sucrose was added at the same time 
from a 50% stock solution, which was sterile filtered through a 250 µL Stericup™ Filter Unit (Millipore, 
Volketswil, Switzerland).  
2.2.2 Storage media 
Storage medium for E. coli strains:  - LB liquid medium, 100 mL 
- Glycerol (Sigma), 100 mL 
 
For storage cultures were harvested to a volume of 1 mL, 0.5 mL of storage medium was added, and the 
sample was immediately stored at -80 °C. 
 
2 x Storage medium for M. bovis BCG (100): - Bacto™ Tryptone (BD, Sparks, MD, USA), 6g 
 - Glycerol, 20 mL 
 - Distilled water, 80 mL 
 
2.2.3 Cultivation 
2.2.3.1 E. coli 
Cultures were grown on LB agar plates or in liquid LB medium at 37 °C unless otherwise indicated. 
The cultures were harvested after 14 to 20 hours. Liquid cultures were shaken with 200 rpm. 
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According to selection criteria media were supplemented with the following antibiotics: 
 
- Ampicillin (Sigma-Aldrich Chemie, Buchs, Switzerland): 100 µg/mL. 
- Kanamycin (Sigma-Aldrich Chemie, Buchs, Switzerland): 50 µg/mL. 
- Hygromycin B (Scientific Inc., San Diego, CA, USA): 100 µg/mL. 
 
2.2.3.2 Mycobacterium bovis BCG 
All vaccine strains arrived in freeze-dried (lyophilized) state and were reconstituted according to the 
manuals of the respective manufactures. Briefly, ampoules were opened under laminar flow. 1 mL of liquid 
Middlebrook 7H9 medium was added and the bacteria were resuspended in medium. The resulting suspension 
was added to 10 mL of Middlebrook 7H9 medium and initially incubated at 37 °C for seven days. The culture 
bottles were weakly shaken every day to prevent cell aggregation. When logarithmic growth was noted by ade-
quately increasing OD600, Middlebrook 7H10 plates were inoculated and incubated for three weeks at 37 °C. 
Additionally sheep blood agar plates were inoculated with 100 µL from the initial 7H9 culture to exclude the 
presence of contaminants. All passage steps, i.e. inoculation from the previous to the next culture medium were 
noted with strain name, media type, culture duration, passage number, date of inoculation and specific remarks 
on phenotypic growth characteristics. All culture techniques were performed in a laminar flow hood dedicated to 
the vaccine study. All solid media culture plates were sealed with UV sterilized parafilm to prevent fungal con-
tamination. 
 
Selective Middlebrook media were supplemented with the following antibiotics as needed: 
 
- Kanamycin (Sigma-Aldrich Chemie, Buchs, Switzerland): 25 µg/mL. 
- Hygromycin B (Scientific Inc., San Diego, CA, USA): 50 µg/mL. 
 
For the counterselection of transformed mycobacteria sucrose was added in the following percentages 
(weight/volume): 2%, 5% and 10%. 
 
For DNA damage induction experiments M. bovis BCG substrains and recA mutants were grown in 
Middlebrook 7H9 medium in the presence of 10% (vol/vol) OADC in motionless tissue culture flasks in a 37 °C 
incubator. To generate DNA damage in SOS response induction experiments as described by Papavinasasunda-
ram et al. (80), mitomycin C (0.2 µg ml-1) was added to 20 mL of growing cultures (at an OD600 of 0.6) and in-
cubated for 24 h. Thereafter bacteria were harvested by centrifugation and prepared for cell lysis and Western 
blot analysis (see 2.15). 
 
Remarks concerning the group assignment of M. bovis BCG vaccine strains in the classification of hu-
man pathogenic organisms: The current official classification list of the Swiss Agency for the Environment, 
Forest and Landscape assigns unmodified, wild-type M. bovis to the group of biosafety level 3 organisms but 
BCG vaccine strains are assigned to the biosafety level 2 group (101). All BCG substrains in this study could be 
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handled in biosafety level 2 laboratories because all six substrains had a solid documentation proofing their use 
as vaccine strains in humans. 
2.3 Minimal inhibitory concentration assay in E. coli 
The degree of resistance towards hygromycin B of E. coli DH5α after transformation with hygromycin 
resistance conferring plasmids was determined on 96-well microtiter plates (Greiner, Frickenhausen, Germany) 
using the following MIC assay: Three different single colonies of DH5α cells were collected from LB plates one 
day after transformation with a plasmid containing the antibiotic resistance gene to be tested and 50 mL LB 
precultures were inoculated with the three colonies. After 14 hours OD600 was determined and all cultures were 
diluted to an equal OD600 of 0.02. 25 µL of diluted culture was then mixed with 25 µL of antibiotic solution 
containing a decreasing amount of antibiotic along a row of a microtiter plate. Final antibiotic culture concentra-
tions from 500 µg mL-1 to 1.95 µg mL-1 with decay of factor two from well to well were chosen. After an incu-
bation period of additional 14 hours, the lowest concentration at which no visible growth could be observed was 
considered as minimal inhibitory concentration. The derived MIC values were compared to MIC values of non-
transformant parental DH5α. 
 
2.4 Generation of electrocompetent cells and transformation 
2.4.1 E. coli 
E. coli XL1-blue or DH5α were streaked on LB agar from frozen stock and incubated over night. A 
single colony was picked and 15 mL of liquid LB was inoculated. 1 L Erlenmeyer culture flasks were filled with 
500 mL of LB and 5 mL from the starter culture was added after an initial incubation of 12 to 14 hours. The 500 
ml cultures were incubated for 3 to 5 hours and at an OD600 of 0.4 - 0.6 the cultures were split on 50 mL falcon 
tubes. Those were cooled on ice water during 15 minutes and thereafter centrifuged at 4 °C with 5000 x g for 20 
minutes. For the subsequent procedures the cells were constantly held at 4 °C. After centrifugation, the super-
natant medium was discarded and the cell pellet was resuspended ice-cold 1 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) pH 7.0-7.2 in half of the initial volume. The content of the falcon tubes was 
pooled to half of the originating number and again centrifuged with 5000 x g for 20 minutes. The washing step 
with HEPES and centrifugation was repeated once with half of the volume and further pooling. After discarding 
the supernatant the cells were resuspended in a total volume of 150 mL cold 10% Glycerol (volume/volume), 
centrifuged with 5000 x g for 20 minutes, the supernatant was discarded, the cells were pooled to one tube and 
50 mL of 10 % glycerol was added. Finally, after an additional centrifugation step the supernatant was discarded 
and 2.5 mL 10% glycerol were added. The cells were aliquoted in 40 µL, frozen in liquid nitrogen and stored at -
80 °C until further use.  
Electroporation was performed with a Gene Pulser XCell™ electroporation system (Bio-Rad Laborato-
ries, Hercules, CA, USA) in 0.1 cm electroporation cuvettes. 40 µL of electrocompetent cells were thawed 
slowly on ice and mixed with 1-2 ng of supercoiled plasmid DNA or 2 µL ligation sample. The transformation 
was achieved with a single pulse at 1.8 kV, 200 Ω and 25 µF followed by immediate addition of 1 mL LB me-
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dium. The transformants were incubated at 37 °C, 200 rpm for 1 hour and then selected on LB plates containing 
the appropriate antibiotics. 
 
2.4.2 Mycobacterium bovis BCG 
The applied technique for the generation of electrocompetent M. bovis BCG was described by Sander et 
al. (5). The mentioned protocol was modified. Cells were not grown in rolling culture flasks but in tissue culture 
flasks, which were not in motion. 
Briefly, after initial reconstitution in Middlebrook 7H9 medium during seven days M. bovis BCG vac-
cine strains were streaked to solid 7H10 medium to obtain single colonies. After approximately three weeks a 
single colony was picked and inoculated in 10 mL of 7H9 in a 25 mL tissue culture flask. The cells were incu-
bated for 10 days at 37 °C and the settled cells were resuspended twice a day by motion. Growth was measured 
by quantifying the optical density at 600 nm. 1 mL of this preculture was inoculated in 200 mL of 7H9 and cul-
tured in tissue culture flasks. Bacteria were cultured until an OD600 of 0.7 to 1.0 was reached (approximately 
after 10 to 14 days). Once the culture had reached the desired density, 0.1 volumes of 2 M glycine (final concen-
tration of 1.5% weight/volume) was added. The incubation was continued for 20 to 24 hours. All following steps 
were performed at room temperature: The culture was split into 50 mL falcon tubes and the cells were collected 
by centrifugation at 5000 x g for 30 minutes. The supernatant medium was discarded and the cells were dili-
gently resuspended in an equal volume of 10% glycerol (i.e. 50 mL per centrifugation tube). The centrifugation 
at 5000 x g was repeated and the cells were resuspended in approximately 40 mL of 10% glycerol per tube. The 
centrifugation was repeated by further decreasing the total volume. The pellet of four centrifugation tubes were 
pooled into two, 40 mL of 10% glycerol added to each of them. After an additional centrifugation step the con-
tent of the two remaining tubes was pooled and 40 mL of 10% glycerol was added. Finally, after a last centrifu-
gation step, 4 mL (1/50th of the initial culture volume) of 10% glycerol was added. For each electroporation 
experiment 400 µL of the final 4 mL cell suspension was taken. In an attempt to increase the number of trans-
formants up to 5 µg of supercoiled plasmid DNA was used in a single transformation experiment (the limiting 
factor for the amount of vector DNA was the decreasing electrical resistance in the transformation cuvette and 
linked to this the risk of light bow formation and vaporization of the sample). Where indicated, 100 mJ cm-2 UV 
irradiation was applied to the vector DNA on a UV Gene Linker 1800 (Stratagene, La Jolla, CA, USA) in order 
to assess whether DNA damage increases gene replacement (102). The DNA and competent cells were gently 
mixed and left aside at room temperature for 5 to 30 minutes. The cells were electroporated in a 4 mm electropo-
ration cuvette with a single pulse and exponential voltage decay using the following settings on a Gene Pulser 
XCell™ electroporation system (Bio-Rad Laboratories, Hercules, CA, USA): 2.5 kV, 25 µF, 1000Ω. An integra-
tive vector pMV361-hyg (103) was included as control for the competency of the cells. Immediately after a sin-
gle electroporation pulse the cells were diluted in 4.6 mL of 7H9 medium and incubated for 24 hours at 37 °C. 
100 µL of the liquid culture was then plated on 7H10 containing the appropriate antibiotic (hygromycin B or 
kanamycin). In addition, 1 mL of the culture was concentrated by centrifugation in a microfuge at 2700 x g, 
resuspended in 100 µL of saline (0.9%) and plated to the appropriate antibiotic 7H10 agar. The plates were 
sealed with parafilm and incubated for 14 to 28 d. Single colonies were picked, amplified, and analysed by PCR 
for genetic characterization of the transformants.  
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2.4.3 Determination of transformation efficiency  
To calculate the efficiency of transformation a 400 µL vial of every batch was transformed with 1 µg 
scDNA of the integrative pMV361-hyg plasmid (103) from a stock solution [1000 ng µL-1]. Transformation 
efficiency per ng of integrative plasmid was calculated as follows:  
 
(a) Calculation of DNA in the transformation sample: 
Formula 1 
v
mc DNADNA =  
cDNA is the concentration of the plasmid DNA in the transformation sample, mDNA is the mass of the added control plasmid, v is volume of the 
transformation sample. For this study 1000 ng of pMV361-hyg was used as a control. The volume of the transformation sample was approx. 
400 µL. This results in a cDNA of 2.5 ng µL-1. 
 
(b) Calculation of the concentration of the control plasmid in the diluted culture after transformation: 
Formula 2 
vd
m
d
cc DNADNAdilutedDNA ==,  
cDNA,diluted is the concentration of the control plasmid in the diluted culture, d is the dilutional coefficient. In this example 4.6 mL of 7H9 
medium was added to the 400 µL sample (d = 12.5, cDNA,diluted = 0.2 ng µL-1). 
 
(c) Concentration of plasmid DNA on the control solid medium plate was calculated: 
Formula 3 
vd
fvmvfcm dilutedDNAdiluteddilutedDNAplateDNA == ..,,  
mDNA,plate is the concentration of the plasmid on the solid medium plate, f is the fraction of the initial culture after transformation that is used 
to inoculate the control plate, and vdiluted is the total volume of the diluted culture. For this experiment 1 mL from the diluted culture was 
centrifuged, cells were harvested and plated on 7H10-Hyg or 7H10-Kan (vdiluted = 1000 µL, f = 0.2, mDNA,plate = 200 ng per plate).  
 
(d) Transformation efficiency (ε) per ng of control plasmid DNA was calculated: 
Formula 4 
dilutedDNAplateDNA fvm
nvd
m
n
==
,
!  
n is the number of colony forming units per plate. 
 
2.5 Macroscopic examination of cultures 
After initial revitalisation in liquid Middlebrook 7H9 medium, all vaccine strains were cultured on Mid-
dlebrook 7H10 agar and colony morphology was examined and photographically documented with a Canon D1 
digital camera and 105 mm macro lens (Canon, Dietikon, Switzerland) on day 21 of culture on solid medium. 
Under appropriate conditions of growth colonies showing fine wrinkling (rugosity) of their surface, which is 
characteristic of certain BCG substrains, can be distinguished from colonies with a smoother non-rugose mor-
phology that is characteristic of some other BCG substrains. 
MATERIAL AND METHODS 
   17
2.6 Microscopic examination of cultures 
The initial liquid 7H9-cultures of the vaccine strains were examined microscopically: A Ziehl-Neelsen 
staining and an Auramine-Rhodamine fluorescence staining was performed. The samples were inspected under a 
standard light microscope at 400 x magnification and fluorescence microscopy for the Auramine-Rhodamine 
stained samples was done on a Zeiss Axioskop microscope (Carl Zeiss, Feldbach, Switzerland) using green exci-
tation light (λ=554 nm) result in emission of red light (λ=627 nm). Bacterial morphology, absence of contami-
nants and staining behaviour was noted and documented with a Canon G1 digital camera. 
 
2.7 Molecular identification 
The current control methods recommended by the WHO (104) and the European Pharmacopoeia Com-
mission (105) for the confirmation of identity of BCG vaccines involve microscopic examination, demonstrating 
their acid-fastness as outlined in 2.6, and macroscopic examination of the characteristic appearance of colonies 
growing on solid medium (as mentioned in 2.5). This methodology is insufficient to differentiate between BCG 
and related pathogenic mycobacteria and it doesn’t allow the separation of BCG substrains. Other means of 
classification rely on biochemical and immunological techniques. Early BCG substrains, derived prior to 1926 
secrete MPB70 antigens (106), produce methoxymycolates (107, 108) and contain two copies of the insertion 
element IS986 (109). Restriction fragment lengths have been used with low reproducibility to differentiate BCG 
substrains (110). 
Recent publications by Marcel Behr and co-workers applying a microarray technique have demon-
strated that substrains of M. bovis BCG own a total of 16 specific chromosomal sequence deletions greater than 
80 bps (Table 2) in comparison to the published M. tuberculosis H37Rv genome (43, 48, 91, 111-115). How-
ever, the close relationship of BCG to the other members of the M. tuberculosis complex, which share > 99.9% 
identity at the DNA level (59), requires very specific molecular tools to distinguish various BCG substrains 
basing on these deletions. Strain specific deletions can be used to differentiate M. bovis BCG from M. tuberculo-
sis and are also applicable to determinate BCG substrains. For this study several known regions of difference 
(RD) were examined with PCR assays in a way to exclude batch contamination and assure identity of the used 
strains.  
In different substrain not only deletions greater than 80 bps have been published but also single nucleo-
tide polymorphisms have been documented, e.g. at locus Mb3700 (Rv3676) which encodes for a putative tran-
scriptional regulatory protein, of the CRP/FNR family (116). A comparative sequence analysis for this locus was 
done too in all included vaccine strains and M. tuberculosis H37Rv.  
In one case a species identification was necessary because the specific culture showed an exceptionally 
slow growth: Genus identification was confirmed by sequencing of the 16S rRNA gene exactly as described in 
(117); the species was determined by characterisation of the genome with respect to RD1. 
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Table 2. Regions of deletion (RD and nRD) from the BCG family of vaccine strains listed according to their location in the M. tuberculosis 
H37Rv genome (in italics: according to the M. bovis AF2122/97 genome). Genome base pair numbers are indicated according to the Geno-
List genome browser at the Pasteur Institute (118). Deletion attributes include the BCGs from which they are deleted, start and end point in 
the H37Rv/AF2122 genome, length in base pairs (bps), and the open reading frames (ORFs) affected by the deletion. Parts of the table have 
been published by Mostowy et al. (115). 
Deleted sequence  Deleted from  Start  End  Length (bps) Affected ORFs 
RD8 BCG Frappier and Connaught  378269  381696  3428  Rv0309 to Rv0312 
  379299  382726 
nRD18  BCG Pasteur, Phipps, Frappier, Connaught, Tice  1332920  1334466  1547  Rv1189 to Rv1191 
  1334170  1335715 
RD14  BCG Pasteur  1998225  2007297  9073  Rv1765c to Rv1773c 
  1988663  1997753  [Rv1766 to Rv1773c (115)] 
RDDenmark/Glaxo BCG Denmark and Glaxo  2052590  2053316  726  Rv1810 to Rv1811 
  2043044  2043768 
RD2  BCG Pasteur, Phipps, Frappier, Connaught, Tice, 2221057  2231845  10788  Rv1978 to Rv1988 
  Denmark, Glaxo, Prague 2199971  2210759 
RD16  BCG Moreau  3817365  3824973  7608  Rv3400 to Rv3405c 
  3769702 3777601 
RDFrappier  BCG Frappier  3914224  3916195  1971  Rv3495c to Rv3497c 
  3859847  3861818 
RDRussia  BCG Russia  4140085  4141688  1603  Rv3697c to Rv3698 
  4077433  4079036 
RD1  All BCG substrains 4350262  4359720  9458  Rv3871 to Rv3879c 
  4286582  4296085 
Total BCG family     46202 
 
2.7.1 Specific PCR for regions of difference and CRP polymorphism 
All PCR assays were performed on either a Tpersonal or a Tgradient Thermocycler (Biometra, Göttin-
gen, Germany), which are essentially comparable devices with heatable lids (heated to 105 °C for the full term of 
the reaction); no mineral oil had to be used. PCR reactions were undertaken in 200 µL thin walled PCR tubes 
(Eppendorf, Bale Switzerland) in a reaction volume of 50 µL. Taq polymerase was used unless otherwise indi-
cated (kit from Roche Diagnostics, Bale, Switzerland). Primers were ordered from Microsynth, Belgach, Swit-
zerland. All primers are listed in Table 4. The primers were compared with the published sequence of M. bovis 
AF2122/97 using BLASTN (DNA vs. DNA) software on the BoviList and TubercuList server (see 2.15.1) to 
exclude mispriming of the oligonucleotides. The PCR analyses were performed on all included BCG strains and 
M. tuberculosis H37Rv. 
 
2.7.1.1 RD8 
The following multi primer assay PCR was set up to determine whether RD8 was deleted or present in a 
specific BCG substrain: Primers RD8-flank.F (10mM, 1µL), RD8-flank.R (10mM, 1µL) and RD8-Rv0309.int.R 
(10mM, 5 µL) were mixed with 10 µL of a DNA mickle preparation (see 2.8.4.1). 23 µL of PCR master mix 
consisting of 4.0 µL dNTP (2.5 mM each), 5.0 µL 10x Taq Gold Puffer (Roche Diagnostics, Bale, Switzerland), 
0.5 µL Taq (Roche Diagnostics, Bale, Switzerland), and 13.5 µL distilled water was added. After composition 
the reaction was immediately started with the listed settings. The expected product lengths were: 292 bps, which 
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indicates absence of RD8 sequence and 286 bps, which indicates its presence. The amplificates were further 
differentiated by sequencing using the RD8-flank-F primer. 
 
Step # Repetitions Duration Temperature Purpose 
1 1 x 5 min 95 °C initial denaturation 
2 10 x 30 s 95 °C denaturation 
3  30 s 59 °C primer annealing 
4  50 s 72 °C elongation 
5 25 x 30 s 95 °C denaturation 
6  30 s 55 °C primer annealing 
7  50 s 72 °C elongation 
8 1 x 7 min 72 °C final elongation 
9  pause   4 °C  
Figure 3. PCR program for RD8-amplification using Taq polymerase. 
 
 
 
Mb   gtgggaaccg gcggttcgac ggccaagatg gatgtctacc aacgcaccgc cgccggctgg       -200 
Mt   gtgggaaccg gcggttcgac ggccaagatg gatgtctacc aacgcaccgc cgccggctgg 
     cagccgctca agaccggtat caccacccat atcggttcgg cgggcatggc gccggaagcc       -140 
     cagccgctca agaccggtat caccacccat atcggttcgg cgggcatggc gccggaagcc 
     aagagcggat atccggccac tccgatgggg gtttacagcc tggactccgc ttttggcacc       - 80 
     aagagcggat atccggccac tccgatgggg gtttacagcc tggactccgc ttttggcacc 
     gcgccgaatc ccggtggcgg Start RD8                           End RD8       - 20 
     gcgccgaatc ccggtggcgg gttg..           3428 bps            ..gacg 
     tcatggtcat cgaccatgag gccttgaccg atcgcgagtt ggcctggtcg cagaccgact       + 60 
     tcatggtcat cgaccatgag gccttgaccg atcgcgagtt ggcctggtcg cagaccgact 
     tcccaagcga agctccggcg cgtttcgagg gcgactcgta taacgaaggc ggcccctgct       +120 
     tcccaagcga agctccggcg cgtttcgagg gcgactcgta taacgaaggc ggcccctgct 
     ggtcgatgcg tctgaacgcg gtcgagcccc ccaaaggacc agcgtggcgg cgaatccggg       +180 
     ggtcgatgcg tctgaacgcg gtcgagcccc ccaaaggacc agcgtggcgg cgaatccggg 
     tgtcgcagtt gctcatcggg                                                   +200 
     tgtcgcagtt gctcatcggg  
Mb   M. bovis AF2122/97 
Mt   M. tuberculosis H37Rv 
 
 
Figure 4. Region of difference RD8, start 378269 (379299), end 381696 (382226), length 3428 bps. Drawing of affected ORFs and sur-
rounding nucleotide sequence (flanking primers underlined) according to the published sequences and base pair numbers (118). 
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2.7.1.2 nRD18 
For investigation of nRD18, PCR reactions with the flanking primer nRD18-flank.F, nRD18-flank.R 
(both of them at a concentration of 10 µM, 1 µL) and 10 µL DNA mickle preparation of the respective strain 
were used. The PCR reaction was set up as previously described for RD8 with an initial denaturation for 5 min-
utes at 95 °C followed by 35 cycles of 95 °C for 30 seconds, annealing at 55 °C for 30 seconds, elongation at 72 
°C for 2 minutes. The products were extended at 72 °C for 7 minutes and stored at 4 °C until agarose gel electro-
phoretic analysis. A non-deleted nRD18 should result in a product length of 1796 bps whereas a deleted should 
give a product of 249 bps. 
 
 
 
Mb   caaaggcgtt gtcgtcgtgg gcgcggatcg ggttggcccg accatcctgc gccactggag      -200 
Mt   caaaggcgtt gtcgtcgtgg gcgcggatcg ggttggcccg accatcctgc gccactggag 
     tcaccccgcc accgtcctgg tagcccagcc ggtgtgcggt caaccggcgg tgctggcctt      -140 
     tcaccccgcc accgtcctgg tagcccagcc ggtgtgcggt caaccggcgg tgctggcctt 
     tgtcaaccga gcgcttgccg gcgtgttggc cctgtcgatc gaggccggca agatcacaaa      - 80 
     tgtcaaccga gcgcttgccg gcgtgttggc cctgtcgatc gaggccggca agatcacaaa 
     aatccatgtc ttagtgcagc Start nRD18                       End nRD18      - 20 
     aatccatgtc ttagtgcagc cttc..           1547 bps            ..tcgc 
     gtcccctgcc ctcgacctgt atggcctgct ctcaccgcgg gccgaccggc atttgctggc        60 
     gtcccctgcc ctcgacctgt atggcctgct ctcaccgcgg gccgaccggc atttgctggc 
     tcggcccgag ttcaaggcga tgttcctcga cgatctgctc aacggtagtc gcaagcagct       120 
     tcggcccgag ttcaaggcga tgttcctcga cgatctgctc aacggtagtc gcaagcagct 
     cgctgcgccg ttcgccgatg tcatcgcctt tgcccgcgac tggggattcc ggctggacga       180 
     cgctgcgccg ttcgccgatg tcatcgcctt tgcccgcgac tggggattcc ggctggacga 
     ggtgaaagtc cccgtccgct                                                   200 
     ggtgaaagtc cccgtccgct. 
Mb   M. bovis AF2122/97 
Mt   M. tuberculosis H37Rv 
 
 
Figure 5. Region of difference nRD18, start 332920 (1334170), end 1334466 (1335715), length 1547 bps. Drawing of affected ORFs and 
surrounding nucleotide sequence (flanking primers underlined) according to the published sequences and base pair numbers (118). 
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2.7.1.3 RD14 
To uncover locus RD14 two different PCR had to be performed: For a deleted RD14, a PCR with two 
flanking primers RD14-flank.F and RD14-flank.R, amplifying a product length of 518 bps, was indicative. The 
respective settings were as mentioned for nRD18 whereby the elongation time could be shortened to 40 seconds 
and the annealing temperature had to be lowered to 46 °C. The second PCR for a non-deleted RD14 used two 
internal primers (RD14-Rv1769.int.F and RD14-Rv1769.int.R) and besides an annealing temperature of 48 °C 
unchanged thermocycler settings. The resulting amplificates were analyzed in a 2% Agarose gel electrophoresis. 
 
 
 
Mb   aactgctcat cggcgctcct ggtgatcgag ggccgcggtt ccggccgaaa atccggttcg      -200 
Mt   aactgctcat cggcgctcct ggtgatcgag ggccgcggtt ccggccgaaa atccggttcg 
     ggttcgggtc gcggttccaa cttgagcgcg gtccgcaact gattcaccgt ggcaaccccg      -140 
     ggttcgggtc gcggttccaa cttgagcgcg gtccgcagct gattcaccgt ggcaacgccg 
     gccaactgcg cataatgcgc atccgaaccc tcacccgccc gccccgcgat caccccaacc      - 80 
     gccaactgcg cataatgcgc atccgaaccc tcacccgccc gccccgcgat caccccaacc 
     tgatccaacg acaaccgccc Start RD14                         End RD14      - 20 
     tgatccaacg acaaccgccc ctcc..           9073 bps            ..tcga 
     gagcagccag cgccgctttt ccattcgcgg ttccgttcaa cgggaagcgg agcccgacgg        60 
     gagcagccag cgccgctttt ccattcgcgg ttccgttcaa cgggaagcgg agcccgacgg 
     ctgagaccgc acgcagccgg taagacgatt cgatctggtc gacaaaccac attcgctggc       120 
     ctgagaccgc acgcagccgg taagacgatt cgatctggtc gacaaaccac attcgctggc 
     cgcgcagtac cgacaggtcg accgtttcgc cgtcggtcgc gcgggcaact cgctcgacgg       180 
     cgcgcagtac cgacaggtcg accgtttcgc cgtcggtcgc gcgggcaact cgctcgacgg 
     tcggccggaa cgccgcggct                                                   200 
     tcggccggaa cgccgcggct  
Mb   M. bovis AF2122/97 
Mt   M. tuberculosis H37Rv 
 
 
Figure 6. Region of difference RD14, start 1998225 (1988663), end 2007297 (1997753), length 9073 bps. 
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2.7.1.4 RDDenmark/Glaxo 
The specific PCR used two flanking primers, RDDenmark-flank.F and RDDenmark-flank.R. An absent 
RDDenmark/Glaxo led to a product length of 234 bps versus 960 bps for a present RDDenmark/Glaxo. The PCR 
settings included the standard 35-cycle amplification with an annealing temperature of 55 °C and an elongation 
time of 1 minute. PCR products were analyzed on a 2% agarose gel. 
 
 
 
Mb   ctctggggag catgaccgga ggtgccctcg gtgccgccgc ccccgccatc tacacgggca      -200 
Mt   ctctggggag catgaccgga ggtgccctcg gtgccgccgc ccccgccatc tacacgggca 
     gtggcgcccg ggcccgcgcc aatgggggaa cgcccagcgc tgagccggtc aagctggagg      -140 
     gtggcgcccg ggcccgcgcc aatgggggaa cgcccagcgc tgagccggtc aagctggagg 
     ctgtcatcgc gcagctacaa aagcaaccgg acgcagtgcg acactggaat gtcgataagg      - 80 
     ctgtcatcgc gcagctacaa aagcaaccgg acgcagtgcg acactggaat gtcgataagg 
     ccgatcttga tggcctgctg Start RDDenmark/Glaxo   End RDDenmark/Glaxo      - 20 
     ccgatcttga tggcctgctg gatc              726 bps              gccg 
     tggtgcgcgg tggtgtggtg cgtccgaggg ggttgcgatg cacccggttc gcctaggctc        60 
     tggtgcgcgg tggtgtggtg cgtccgaggg ggttgcgatg cacccggttc gcctaggctc 
     aaactgctgt taacctgcgc gtggttggct gccgtggccg tcttgcgatc gggaaggact       120 
     aaactgctgt taacctgcgc gtggttggct gccgtggccg tcttgcgatc gggaaggact 
     cggcgtcatg caaacgctga ctgtcgccga tttcgctctc cggctggccg tcggagtggg       180 
     cggcgtcatg caaacgctga ctgtcgccga tttcgctctc cggctggccg tcggagtggg 
     ttgcggggcc attatcgggc                                                   200 
     ttgcggggcc attatcgggc 
Mb   M. bovis AF2122/97 
Mt   M. tuberculosis H37Rv 
 
 
Figure 7. Region of difference RDDenmark/Glaxo, start 2052590 (2043043), end 2053316 (2043768), length 726 bps. 
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2.7.1.5 RD2 
To characterise RD2 the following PCR multiprimer assay was performed: A 50 µl reaction mixture 
with the Triple Master PCR System (Vaudaux-Eppendorf, Bale, Switzerland) was prepared; 1 µL of two flank-
ing primers (RD2-flank.F and RD2-flank.R) at a concentration of 10 mM, 1 µL of a 50 mM internal primer 
(RD2-Rv1979-int.R), 5 µL High Fidelity buffer, 0.5 µL Triple Master PCR enzyme blend, 4 µL of dNTP (each 
deoxynucleoside triphosphate at a concentration of 2.5 mM), 10 µL of a mickle DNA preparation and distilled 
water ad 50 µL were prepared in a 500 µL PCR tube. After denaturation at 95°C for 3 minutes, the reaction 
mixture was incubated for 40 cycles at 95 °C for 25 seconds and 15 seconds at 54 °C, followed by 80 seconds at 
72 °C, and final extension for 7 minutes at 72 °C. The following product lengths were expected: For an absent 
RD2 1043 bps, for a present RD2: 1884 bps. 
 
 
Figure 8. Region of difference RD2, start 2221057 (2199971), end 2231845 (2210759), length 10788 bps. 
 
Mb   agcggtctca tagcattgcg aacacgggac gtcgagaggg gaagagctgc catgggtgag      -200 
Mt   agcggtctca tagcattgcg aacacgggac gtcgagaggg gaagagctgc catgggtgag 
     gcgaacatcc gcgagcaggc gatcgccacg atgccacggg gtggccccga cgcgtcttgg      -140 
     gcgaacatcc gcgagcaggc gatcgccacg atgccacggg gtggccccga cgcgtcttgg 
     ctggatcgtc gattccagac cgacgcactg gagtacctcg accgcgacga tgtgcccgat      - 80 
     ctggatcgtc gattccagac cgacgcactg gagtacctcg accgcgacga tgtgcccgat 
     gaggtcaaac agaagatcat Start RD2                           End RD2      - 20 
     gaggtcaaac agaagatcat tgcc..          10788 bps            ..gcgc 
     gggtggtcgc cgtggagttg cacccgcgac gagtcggtgt cctccgcgag cgattccctg        60 
     gggtggtcgc cgtggagttg cacccgcgac gagtcggtgt cctccgcgag cgattccctg 
     gcattaccgt ggtgcacgcg gacgccgcct cgatccggtt gcccggccgg ccgttccggg       120 
     gcattaccgt ggtgcacgcg gacgccgcct cgatccggtt gcccggccgg ccgttccggg 
     ttgtggcgaa cccgccgtac gggatttcgt cccgcctgct gcggacgctg ctggcaccca       180 
     ttgtggcgaa cccgccgtac gggatttcgt cccgcctgct gcggacgctg ctggcaccca§ 
     acagcgggct tgtcgcggcc                                                   200  
     acagcgggct tgtcgcggcc  
Mb   M. bovis AF2122/97 
Mt   M. tuberculosis H37Rv 
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2.7.1.6 RDFrappier 
RDFrappier was examined with a multiprimer PCR as follows: 1 µL RDFrappier-fl.F (10 pM), 1 µL 
RDFrappier-fl.R (10 pM), 1 µL RDFrappier-Rv3495c-int.R (50µM), 4.0 µL dNTP (2.5 mM each), 5.0 µL 10x 
Taq Gold Puffer (Roche Diagnostics, Bale, Switzerland), 0.5 µL Taq (Roche Diagnostics, Bale, Switzerland), 
5.0 µL template (DNA mickle preparation), and distilled water ad 50 µL were assorted. The thermocycler set-
tings included denaturation at 95 °C for 5 minutes, 35 cycles of 95 °C for 30 seconds, 50 °C for 30 seconds, and 
72 °C for 20 seconds. Final extension was performed at 72 °C for 3 minutes. The expected product lengths were 
177 bps for a M. tuberculosis like locus and 229 bps for the deleted locus. 
 
 
 
Mb   caatgatctc ttccaacgca ccgacgttac ccttgttgac caccaccccc agcgccgaga     - 200 
Mt   caatgatctc ttccaacgca ccgacgttac ccttgttgac caccaccccc agcgccgaga 
     aaacctcctc ggtggtgggg aatcggtcgg tgttggcctc ggtgattctc gagccgtcaa     - 140 
     aaacctcctc ggtggtgggg aatcggtcgg tgttggcctc ggtgattctc gagccgtcaa 
     ccaacctccc ggtcggcggg cggtccgtcg gtggcgccag ctctacatgt aacgaaccca      - 80 
     ccaacctccc ggtcggcggg cggtccgtcg gtggcgccag ctctacatgt aacgaaccca 
     gcagcgaggt ctgggagacc Start RDFrappier             End RDFrappier      - 20 
     gcagcgaggt ctgggagacc ttcg             1971 bps              aaag 
     ccggaaatct gcgctgcaac atcgtcgatc ccagagatca acgcgctgag cgcggcccgc        60 
     ccggaaatct gcgctgcaac atcgtcgatc ccagagatca acgcgctgag cgcggcccgc 
     cgggcatcga gcgccgcaaa caactggttg ccgtcctcga ccagcttgtt gacctgttcg       120 
     cgggcatcga gcgccgcaaa caactggttg ccgtcctcga ccagcttgtt gacctgttcg 
     gcgcgttcgg acaacaccga tgtcaccgac ttggcgtgcg ccagcaggcc ttgcagcgct       180 
     gcgcgttcgg acaacaccga tgtcaccgac ttggcgtgcg ccagcaggcc ttgcagcgct 
     tcgtcgcgac gattcagggc                                                   200 
     tcgtcgcgac gattcagggc 
Mb   M. bovis AF2122/97 
Mt   M. tuberculosis H37Rv 
 
Figure 9. Region of difference RDFrappier, start 3914224 (3859847), end 3916195 (3861818), length 1971 bps. 
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2.7.1.7 RDRussia 
To examine the locus RDRussia two primers flanking the prospective deletion were used (RDRussia-
flank.F and RDRussia-flank.R). As both primers have high annealing temperatures and the amplificates have a 
high GC-content of more than 65% for both amplificates the GC-Rich PCR System (Roche Diagnostics, Bale, 
Switzerland) was used for this reaction (for composition of PCR master mix see 2.7.1.9). The PCR reaction was 
performed with an initial denaturation at 95 °C for 3 minutes, 35 cycles of 95 °C for 30 seconds, followed by 30 
seconds at 58 °C, and 2 minutes at 72 °C. After 35 cycles a final extending step at 72 °C was applied. Due to 
high primer melting temperatures GC-bond dissolving agents that have to be used to perform this PCR. More 
favourable primer pairs to examine this region could not be determined because of a persistently high GC-
content of the genomic sequence of RDRussia. 
For a present H37Rv homologue sequence at RDRussia locus, a 1956-bp amplificate was expected, for 
an absent a fragment length of 353 bps was expected.  
 
 
 
Mb   cgtgatggcg catgagcgcg acgaggtggg cgtcgggaac cagattgcct cgcggcttga     - 200 
Mt   cgtgatggcg catgagcgcg acgaggtggg cgtcgggaac cagattgcct cgcggcttga 
     ccgggtcggc tactcgccga tagacgggcc agaatccgtt ggcctcgccg acctgccgca     - 140 
     ccgggtcggc tactcgccga tagacgggcc agaatccgtt ggcctcgccg acctgccgca 
     cgtgcggtcg tgaggtgaat tgctcgatgt tttcgacggc gacctcaggc gccagcggcg      - 80 
     cgtgcggtcg tgaggtgaat tgctcgatgt tttcgacggc gacctcaggc gccagcggcg 
     cacccaacaa cgtcggatgg Start of RDRussia           End of RDRussia      - 20 
     cacccaacaa cgtcggatgg gtga             1603 bps              cgaa 
     tttcctggca gccgccaggt acggcatgga cgcccagttg gattggccgg gcttgggcga        60 
     tttcctggca gccgccaggt acggcatgga cgcccagttg gattggccgg gcttgggcga 
     ggtgacgacg cgggagttgg tgttgggcac gttgttgcca atggcacacg agggactgcg       120 
     ggtgacgacg cgggagttgg tgttgggcac gttgttgcca atggcacacg agggactgcg 
     gcggtggggt gtcgacgcgg aggtacgcga ccggttcctg ggtgtcatcg gcggtcgcgc       180 
     gcggtggggt gtcgacgcgg aggtacgcga ccggttcctg ggtgtcatcg gcggtcgcgc 
     ccagaccggc cgcaacggcg                                                   200 
     ccagaccggc cgcaacggcg                                             
Mb   M. bovis AF2122/97 
Mt   M. tuberculosis H37Rv 
 
Figure 10. Region of difference RDRussia, start 4140085 (4077433), end 4141688 (4079036), length 1603 bps. 
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2.7.1.8 RD1 
RD1, which has been shown to be absent in all BCG strains was examined using a multiplex PCR technique as 
described by Talbot et al. (119). Briefly, a PCR containing primers ET1 and ET3, which are complementary to 
regions flanking RD1, and primer ET2 (complementary to DNA within RD1 deletion) was prepared. In strains 
without RD1, primers ET1 and ET3 bind and amplify a 200-bp region. In strains with RD1, ET2 and ET3 yield a 
150-bp product (Figure 10). The PCR mix contained AmpliTaq Gold PCR buffer, 200 mM each deoxynucleo-
side triphosphate, 1.25 U of Taq DNA polymerase (AmpliTaq Gold; Roche, Bale, Switzerland), 5 pmol each of 
primers ET1 and ET3, and 25 pmol of ET2. The mixture was denatured for 3 min at 95 °C and cycled 40 times 
to 94 °C for 30 s and 65 °C for 1 min, followed by a final 10-min extension at 72 °C. The published protocol was 
modified, namely by simplifying the composition of the PCR reaction: PCR was performed without separate 
addition of KCl, gelatine and Tris-HCl. Instead of those the 10 x AmpliTaq Gold buffer as supplied by Roche 
was used. PCR amplificate band size was estimated on a 2% agarose gel by comparison to a 1500-bp DNA lad-
der (Fermentas, Hannover, MD, USA).  
 
Figure 11. Multiplex PCR design. Wild-type M. tuberculosis complex DNA is represented by the parallel lines in the top diagram. The 
shaded region contains the 9.5-kb sequence RD1. RD1 is deleted in M. bovis BCG DNA, represented by the dashed lines in the lower dia-
gram. The PCR primers ET1, ET2, and ET3 are shown as arrows oriented in the direction of amplification. This figure was adapted from 
(119), copyright 1997, American Society for Microbiology. 
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Mb   cctgctggac gcggtgccgg acacccatct gctgggcgcc ggcgcgatca accgcaacag     - 200 
Mt   cctgctggac gcggtgccgg acacccatct gctgggcgcc ggcgcgatca accgcaacag 
     cgcgtcgcta gacgaggccg ttcaagcact ggcggtcaac ctgaagaagc ggttgccgcc     - 140 
     cgcgtcgcta gacgaggccg ttcaagcact ggcggtcaac ctgaagaagc ggttgccgcc 
     gaccgacctg acgacggcgc agctacgctc gcgttcgtgg tggagcggat ttgacgtcgt      - 80 
     gaccgacctg acgacggcgc agctacgctc gcgttcgtgg tggagcggat ttgacgtcgt 
     gcttctggtc gacgattggc Start of RD1                     End of RD1      - 20 
     gcttctggtc gacgattggc acat             9458 bps              ttcc 
     acccagccgc ccggatccag catctgtctg gcatagctgc ccgtcggcct ggtaatactc        60 
     acccagccgc ccggatccag catctgtctg gcatagctgc ccgtcggcct ggtaatactc 
     atcccctact gccctcccca aaccgccaga tcgcctcgcg gatcaccgtc cggttggcct       120 
     atcccctact gccctcccca aaccgccaga tcgcctcgcg gatcaccgtc cggttggcct 
     ccggcatttc acgccggctc ggccgctgga tccaccccgc gccggtattc gcagtaaccc       180 
     ccggcatttc acgccggctc ggccgctgga tccaccccgc gccggtattc gcagtaaccc 
     gttgaatccg cgcgcatgat                                                   200 
     gttgaatccg cgcgcatgat                                             
Mb   M. bovis AF2122/97 
Mt   M. tuberculosis H37Rv 
 
Figure 12. Region of difference RD1, start 4350262 (4286582), end 4359720 (4296085), length 9458 bps. Primers ET1 (forward) and ET3 
(reverse) are underlined. 
 
2.7.1.9 Mb3700/Rv3676 (cAMP receptor protein, CRP) 
The amplification and sequencing of the Rv3676 region was performed as described by Spreadbury et 
al. (116) with minor modifications. The published primer sequences in their study are part of the Rv3676 gene 
and don’t allow sequencing of the full gene length directly from the primary amplificate. To amplify 
Mb3700/Rv3676 from genomic DNA two flanking primers Rv3676_for and Rv3676_rev (Figure 13) derived 
from the published sequence of M. bovis AF 2122/97 (120) were ordered. The expected amplificate had a length 
of 882 bps and a GC-content of 64%. Approximately 10 ng of genomic DNA were used as a template and ampli-
fied using the two flanking primers and the GC-Rich PCR System (Roche Diagnostics, Bale, Switzerland) in a 
50 µL reaction with a composition according to the instructions of the manufacturer. No GC-Rich resolution 
buffer was added. The samples were incubated using a touchdown PCR protocol: Initial denaturation at 95 °C 
for 3 minutes was followed by 10 cycles of 95 °C for 30 seconds, 61 °C for 30 seconds and 72 °C for 50 seconds 
which was followed by 25 equal cycles with a lowered annealing temperature of 58 °C in stead of 61 °C. Final 
product extension was performed at 72 °C for 7 minutes. 
The PCR products were purified by agarose gel extraction and used for direct DNA sequencing with the 
amplification primers mentioned above. The resulting sequence files were assembled and compared using  
SeqMan™ II (DNASTAR, Madison, WI, USA) sequence alignment software and sequence differences were 
noted. 
MATERIAL AND METHODS 
 28 
 
Figure 13. Rv3676/Mb3700 and position of the flanking primers Rv3676_for and Rv3676_rev. Published point mutations (116) are marked 
with the corresponding base pair number (counting from the start of Rv3676). The amplificate length is 882 bps. 
2.7.1.10 Amplification and sequencing of recA 
For sequence comparison, recA was amplified using Pfu DNA polymerase (Promega). A large-scale ge-
nomic DNA preparation (2.8.4.2) from a Middlebrook 7H10 plate culture served as template. 50 ng of genomic 
DNA was added to a master mix containing dNTPs (final concentration 200 µM each), recA3_start and 
recA3_stop primers (final concentration 0.8 µM each) and 10 x PCR buffer with MgSO4 (supplied with the po-
lymerase kit), and 1.25 u Pfu DNA polymerase. Cycling conditions were an initial 1 min 30 s lasting denatura-
tion step at 95 °C, followed by 35 amplificatory cycles including denaturation at 95 °C for 30 s, primer annealing 
at 59 °C for 30 s, and elongation at 72 °C for 4 min (corresponding to an amplification product of 2562 bps). 
Final elongation at 72 °C was performed during 5 min. The PCR tube was then kept at 4 °C until fragment 
analysis by agarose gel electrophoresis and fragment excision was performed. 200 ng of the amplificated DNA 
were used for subsequent sequencing (see 2.10) using recA binding primers (Table 4). 
2.8 DNA methods 
2.8.1 Plasmid extraction from E. coli 
For small scale plasmid isolation, 3 to 5 mL of LB containing the appropriate antibiotic was inoculated 
with a single bacterial colony from solid medium and incubated over night at 37 °C and constant shaking at 200 
rpm. The cells from 1.5 mL culture were harvested by centrifugation at 10000 x g in a microfuge during 5 min-
utes. The following isolation steps were performed with a NucleoSpin® Plasmid Kit (Macherey Nagel, Düren 
Germany) according to the user’s manual of the producer. This kit uses the alkaline SDS lysis protocol and ad-
sorbs the plasmid DNA on a column with treated silica membrane from where it can be eluted with water or TE 
buffer.  
For medium scale plasmid preparations a single bacterial colony from an overnight culture was inocu-
lated to 150 mL of LB supplemented with the appropriate antibiotic. The culture was incubated for 10 to 14 
hours at 37 °C and 200 rpm. Cells were collected by centrifugation for 15 minutes at 5000 x g. The plasmid 
preparation was performed with Promega’s PureYield™ Plasmid Midiprep System (Catalys AG, Wallisellen, 
Switzerland) according to the instructions of the producer. This kit uses the alkaline SDS lysis protocol too and 
the plasmid DNA is finally eluted in a volume of 300 µL. For this study DNA was generally eluted with water to 
prevent enzyme inhibition by buffer contents (especially EDTA) in subsequent restriction assays. 
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2.8.2 Agarose gel electrophoresis and analysis 
According to separatory needs (DNA lengths) 0.8% to 2% Agarose gels were produced from highly 
pure Agarose and TAE buffer pH 8.3 and immerged in TAE running buffer. DNA samples were mixed with 6 x 
loading dye (Fermentas) and filled in the gel pouches. DNA length separation was achieved with field strength 
of 5 V/cm for 1 to 2 hours. Gels were transferred to a 0.0002% ethidium bromide bath for 15 minutes and 
washed in deionised water during 5 minutes. Afterwards gels could be analysed under UV light (λ=312 nm). 
 
2.8.3 DNA purification 
2.8.3.1 Ethanol precipitation 
Ethanol precipitation was used to remove salts from DNA solutions and to concentrate DNA samples. 
To precipitate DNA in water solutions 2.5 M sodium acetate solution was added to a final concentration of 0.3 
M. 2.5 volumes of 100% ethanol was added and the solution was cooled at -80 °C for an hour or at -20 °C over 
night. DNA was collected by centrifugation at 16000 x g in a microcentrifuge. The pelletted DNA was then 
washed twice with 70% ethanol (-20 °C) and dried at room temperature under a vacuum of 0.25 mbar in a 
Speedvac Concentrator (Inotech AG, Wohlen, Switzerland). The pellet was solved in an appropriate volume (50 
- 200 µL, according to DNA amount) of distilled water or TE buffer after purification. 
 
2.8.3.2 Phenol extraction 
Phenol extraction was used to purify chromosomal DNA and to remove enzymes after enzymatic ma-
nipulations of DNA. To extract DNA, an equal volume of phenol/chloroform/isoamyl alcohol 25/24/1 mixture 
was added to a DNA solution. The resulting mixture was centrifuged at 16000 x g for 20 minutes and the aequos 
phase was pipetted in a new microcentrifuge tube. The DNA was then precipitated using ethanol precipitation 
described above. 
 
2.8.3.3 Gel extraction 
Gel extraction was applied to isolate a specific fragment from a DNA sample. Therefore a digested 
DNA sample was loaded on an Agarose gel and separated electrophoretically as described above. After separa-
tion the gel was stained with ethidium bromide and analyzed under UV light. The gel piece containing the de-
sired DNA fragment was cut out under direct UV light visualization (λ=312 nm, minimal UV exposure time). 
The DNA was isolated from the gel piece using a QIAquick gel extraction kit (Qiagen, Bale, Switzerland) ac-
cording to the manufacturer’s user’s manual. 
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2.8.4 Isolation of chromosomal DNA from Mycobacterium bovis BCG 
2.8.4.1 Minimal scale DNA preparation 
For PCR screening of transformants the following DNA preparation method was applied (117): A small 
colony from a slant was picked and transferred into a 1.5 mL screw cap microcentrifuge tube with 50 µL 0.9% 
NaCl. One or two 1 mm acid washed sterile glass beads (Sigma-Aldrich Chemie, Buchs, Switzerland) were 
added and the tube was vortexed shortly to separate the cells. Alternatively the colony was suspended using a 
volume of 400 µL normal saline and a 26 gauche needle by several strokes through the needle. 10 µL were re-
moved for further culture. The remaining cell suspension was heated for 10 min at 80 °C to inactivate the myco-
bacteria. The tube was centrifugated at maximum speed (approximately 17000 x g) in a microcentrifuge for 10 
minutes. The supernatant and glass beads were discarded. 100 µL of TE buffer and a loopful of acid washed 
glass beads (100 µm diameter) were added to the cell pellet and the tubes were placed on mickle tissue disinte-
grator at maximal speed for 2 minutes. Then the sample was centrifugated at maximum speed in a microcentri-
fuge for 5 minutes. The supernatant was transferred in a new tube, 5 µL aliquots were used for PCR. 
 
2.8.4.2 Large-scale DNA preparation 
For Southern blot analyses and sequencing DNA was prepared from a three week culture on Middle-
brook 7H10. The bacteria were harvested from half a Petri dish and suspended in 340 µL of TE buffer. The bac-
teria were heat inactivated at 80 °C during 20 minutes. 4 µL 10% Tween-80 and 20 µL lysozyme (40 mg/mL, 
Roche, Bale, Switzerland) were added. The sample was incubated at 37 °C for two hours. Afterwards 40 µL 
10% SDS and 20 µL proteinase K (2 mg/mL, Roche, Bale, Switzerland) were gently mixed to the sample. The 
preparation was incubated at 60 °C for one hour. DNA was extracted by adding 400 µL phe-
nol/chloroform/isoamyl alcohol 25/24/1 and centrifugation with 16000 x g at 4 °C. Thereby the DNA was solved 
in the aequous phase which was transferred in a new tube. 8 µL 5 M NaCl and 1 mL of ethanol were added to 
precipitate the DNA. The sample was cooled to -80 °C for one hour and centrifugated with 16000 x g for 20 
minutes. The supernatant was carefully removed with a vacuum pipette. The DNA pellet was washed twice with 
500 µL cold 70% Ethanol, dried under a vacuum of 200 mbar in a Speedvac Concentrator (Inotech AG, Wohlen, 
Switzerland) and depending on the visual size of the pellet 50 to 200 µL distilled water were used to solve the 
pellet. DNA solutions were stored at 4 °C for short terms (1 week) and at -20 °C for longer periods. 
2.8.5 Determination of DNA concentration 
Nucleic acids were quantified by measuring absorbance at 260 nm in an Ultrospec® 2100 Pro or Gene-
Quant™ ultraviolet/visible light spectrometer (Amersham Bioscience, Otlefingen, Switzerland). A DNA solution 
with an optical density of 1.0 at 260 nm has a concentration of 50 µg/mL in a 10 mm path length quartz cell. 
Linear regression was used to calculate concentration in a 100 µL volume in a 1:50 diluted sample. For determi-
nation of DNA purity, the A260/280 and A260/230 coefficients were determined photometrically. An A260/280 < 1.8 
indicated contamination of the DNA preparation with protein or aromatic substances such as phenol; while an 
A260/230 > 2.0 indicated possible contamination with RNA. 
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2.8.6 Southern blot analysis 
2.8.6.1 Blotting 
For Southern blot analysis, 1 µg of genomic DNA was digested over night with an appropriate restric-
tion endonuclease and separated by gel electrophoresis in a 1.2% agarose gel. The gel was immerged in 0.25 M 
HCl for 10 minutes and then the bath solution was exchanged for a denaturation solution (1.5 M NaCl, 0.5 M 
NaOH) and shaken for 15 min. For another 15 minutes, the gel was incubated in neutralization solution (0.3 M 
NaCl, 0.03 M sodium citrate). Finally the gel was transferred to a bath of 2 x SSC (1:10 dilution of 20 x SSC 
stock: 30 mM sodium citrate, 3 M NaCl, pH 7.0) and incubated for 15 minutes. The DNA was blotted from the 
gel to a Hybond-N membrane (Roche, Bale, Switzerland) using a Vacu-Blot System (Biometra, Göttingen, Ger-
many) with 20 x SSC as blotting buffer and a vacuum of 500 mbar for 90 minutes. After blotting, the Hybond-N 
membrane was quickly washed in 2 x SSC and the DNA was bound to the membrane by crosslinking with 1200 
mJ cm-2 UV radiation on each side in an UV Gene Linker 1800 (Stratagene, La Jolla, CA, USA). 
2.8.6.2 Hybridization 
Prehybridization was performed by incubation at 42 °C for one hour in hybridization tubes containing 
10 mL of hybridization solution (0.7 g SDS, 5 mL of formamide, 2.5 mL of 20 x SSC, 0.5 mL of 1 M NaPO4, 10 
mg N-laurosylsarcosine, 2 mL 10 x blocking solution as described in 2.8.6.3). Hybridization was performed at 
42 °C over night by addition of 100 ng digoxigenin (DIG) labelled probe to the hybridization solution. The probe 
was labelled with a DIG-High Prime DNA Labelling Kit (Roche, Bale, Switzerland) according to the instruc-
tions of the manufacturer. The approximate concentration of the DNA probe stock was determined by 5 serial 
logarithmic dilutions of the probe and comparison of the signal strength on photographic film with a dilution 
series of labelled DNA with known concentration (supplied in kit) in a CDP-Star assay mentioned under para-
graph 2.8.6.3. 
2.8.6.3 Detection 
After decanting of the hybridization solution, the membrane was washed twice with 2 x SSC / 0.1% 
SDS solution for 5 minutes at room temperature and twice with 0.1 x SSC / 0.1% SDS solution for 15 minutes at 
68 °C. Subsequently, the membrane was shortly equilibrated in 50 mL washing buffer. The washing buffer was 
compounded from maleic acid buffer (1L maleic acid buffer: 11.6 g maleic acid, 8.7 NaCl, 7.8 g NaOH, pH 7.5) 
by addition of 0.6% (volume/volume) 10% Tween-80. After washing, the binding capacity of the membrane was 
blocked by incubation at room temperature for 30 minutes with 50 mL 1 x blocking solution (10 x blocking 
solution: 25 g skim milk powder, maleic acid ad 250 mL). To detect DIG labelled DNA fragments, the blocking 
solution was replaced by another 50 mL of blocking solution containing 2.5 µL of Anti-digoxigen-alkaline-
phosphatase Fab Fragments (Roche, Bale, Switzerland). After 30 min of incubation the membrane was washed 
twice for 15 minutes with washing buffer (same composition as mentioned above). The membrane was pored 
off, and 50 mL of detection buffer was added (0.1 M Tris-HCl, 0.1 M NaCl, and pH 9.5). After 3 minutes the 
detection buffer was replaced by 50 mL of CDP-Star (ultra-sensitive chloro-substituted 1,2-dioxetane chemilu-
minescent substrate for alkaline phosphatase, Roche, Bale, Switzerland) diluted 1:100 in detection buffer and 
incubated at room temperature and light protection for 5 minutes. The membrane was pored off and welded in a 
polyethylene bag. The chemiluminescent membrane was photographed with BioMax Light film (Eastman Kodak 
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Company, Rennes, Switzerland) with different exposure times in the range from 2 to 60 minutes (depending on 
the relative signal intensity). 
 
2.8.7 Specific Southern analysis for the examination of the recA locus 
Genomic DNA from BCG transformants was prepared as previously described and digested with SmaI. 
A 412 bps NheI/NotI fragment from plasmid pBS-KSII(-)-recA (H37Rv base pairs 3051677 to 3052088; accord-
ing to TubercuList) was labelled with digoxigenin and used as probe. The probe is situated at the 5’ end of the 
recA gene. After digestion with SmaI and hybridization with the mentioned probe, wild-type recA allele was 
expected to result in a labelled 2.0 kbs fragment. Single crossover transformants should either show a 2.0 kbs 
wild-type fragment and an additional fragment at 9.6 kbs demonstrating plasmid integration 5’ of the recA gene 
or a signal at 4.0 kbs and at 5.6 kbs for integration 3’ downstream of the recA gene. The recA knock-out mutant 
should result in a single signal at 5.9 kbs (Figure 47). 
 
2.9 Enzymatic manipulations of DNA 
2.9.1 Endonucleolytic restriction digestion of plasmid DNA 
For analytical restriction digestion a minimal quantity of 200 ng supercoiled plasmid DNA or chromo-
somal DNA was mixed with the restriction enzymes mentioned in Table 3. 
For preparational reactions 0.5 to 1 µg DNA was digested with 10 units of the respective endonu-
cleolytic restriction enzyme and the specific 10 x concentrated buffer that was recommended by the enzyme 
manufacturer was added in correct dilution. The sample was incubated for at least two hours at the appropriate 
temperature (usually 37 °C unless especially noted). Digestions for cloning experiments and Southern blot 
analyses were performed over night to allow almost complete digestion. 
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Table 3. List of restriction enzymes used in this study. 
Name (synonyms) recognition sequence (^ marks cut) Supplier 
ApaI 5'-G G G C C^C-3' Fermentas, Nunningen, Switzerland 
 3'-C^C C G G G-5'  
BclI 5'-T^G A T C A-3' Fermentas 
 3'-A C T A G^T-5'  
BglII 5'-A^G A T C T-3' Fermentas 
 3'-T C T A G^A-5'  
Bpu1102I 5'-G C^T N A G C-3' Fermentas 
 3'-C G A N T^C G-5'  
EcoRV (Eco32I) 5'-G A T^A T C-3' Fermentas 
 3'-C T A^T A G-5'  
HindIII 5'-A^A G C T T-3' Fermentas 
 3'-T T C G A^A-5'  
MunI (MfeI) 5'-C^A A T T G-3' Fermentas 
 3'-G T T A A^C-5'  
NheI 5'-G^C T A G C-3' Fermentas 
 3'-C G A T C^G-5'  
NotI 5'-G C^G G C C G C-3' Fermentas 
 3'-C G C C G G^C G-5'  
NsiI (Mph1103I) 5'-A T G C A^T-3' Fermentas 
 3'-T^A C G T A-5'  
PstI 5'-C T G C A^G-3' Amersham Biosciences, Otelfingen, Switzerland 
 3'-G^A C G T C-5'  
SacI 5'-G A G C T^C-3' Fermentas 
 3'-C^T C G A G-5'  
SapI (LguI) 5'-G C T C T T C (N)1^-3' NEB, Ipswich, MA, USA 
 3'-C G A G A A G (N)4^-5'  
ScaI 5'-A G T^A C T-3' Amersham Biosciences 
 3'-T C A^T G A-5'  
SexAI 5'-A^C C N G G T-3' NEB 
 3'-T G G N C C^A-5'  
SmaI 5'-C C C^G G G-3' Fermentas, NEB 
 3'-G G G^C C C-5'  
SnaBI (Eco105I) 5'-T A C^G T A-3' Fermentas 
 3'-A T G^C A T-5'  
SpeI (BcuI) 5'-A^C T A G T-3' Fermentas 
 3'-T G A T C^A-5'  
SphI (PaeI) 5'-G C A T G^C-3' Fermentas 
 3'-C^G T A C G-5'  
Van91I (PflMI) 5'-C C A N N N N^N T G G-3' Fermentas 
 3'-G G T N^N N N N A C C-5'  
XbaI 5'-T^C T A G A-3' Fermentas 
 3'-A G A T C^T-5'  
 
2.9.1.1 Dephosphorylation of DNA 
In cloning experiments the vector plasmid DNA was usually dephosphorylated at its 5’-ends. This was 
done by adding 6 units (in 6 µl) of SAP (shrimp alkaline phosphatase, Roche, Bale, Switzerland) and 4 µL of 10 
x buffer (also from Roche, comes in same kit) to up to 10 µg of digested, open circle vector DNA in a total reac-
tion volume of 40 µL. The mixture was incubated for two hours at 37 °C. The enzyme was inactivated by heat-
ing to 65 °C for 15 minutes. The DNA was purified by gel extraction or phenol extraction for further use. 
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2.9.1.2 Blunting of DNA fragments 
In order to produce blunt ends DNA was treated with recombinant T4 DNA polymerase (Roche, Bale, 
Switzerland) in presence of an overextend of dNTPs. T4 polymerase is a DNA dependent DNA polymerase that 
combines 5’-3’ polymerase with 3’-5 exonuclease activity and lacks 5’-3’ exonuclease activity. In a total reac-
tion volume of 50 µL purified DNA (up to 5 µg) was added to 1 unit (in 1 µL) of T4 DNA polymerase, the pro-
vided 10 x reaction buffer and dNTPs were added to a final concentration of 0.4 mM each. The reaction was 
incubated for exactly 15 minutes at 37 °C and stopped through 20 minutes lasting thermal inactivation at 80 °C.  
 
2.9.1.3 Ligation 
For ligation reactions DNA was purified as mentioned above and different molar ratios of vector and in-
sert were prepared. A molar ratio of 1:3 (vector: insert) was included in the ligation experiment where exact 
concentration of the DNA samples could be determined (using absorption photometry). Quantities to be used 
were calculated using Formula 5 indicated below. Ligation reactions were performed in a total volume of 10 or 
20 µL with 1 unit (in 1 µL) T4 DNA ligase (Roche, Bale, Switzerland) and the supplied 10 x ligation buffer.  
 
Formula 5. 
vector
insertvector
insert l
rlmm !!=  
minsert: mass of insert to be used in ng, mvector: mass of vector in ng, linsert: length of insert in base pairs, lvector: length of vec-
tor in base pairs, r: molar ratio vector : insert 
2.10 DNA Sequencing 
DNA sequencing was done on the basis of a semi automated protocol using the BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, Forster City, CA, USA). The kit uses Sanger’s PCR chain-
termination sequencing method modified with fluorescence marked dideoxynucleotides (ddNTPs) as PCR ter-
minator (121) in a defined molar ratio to unmarked deoxynucleotides (dNTPs). The primary reaction is a single 
primer PCR to generate labelled amplificate fragments which end on a fluorescence marked ddNTP. Sequencing 
PCR started from a previously determined ssDNA primer (see Table 4 for complete list of primers used in this 
study). In a thin walled 0.5 mL PCR tube 600 to 1,000 ng of template DNA was given to 4 µL BigDye® reaction 
premix (ddNTPs, dNTPs and polymerase), 2 µL 5 x BigDye® buffer, the appropriate sequencing primer at a 
concentration of 1 pmol µL-1 and deionised water to a final reaction volume of 20 µL were compounded. The 
following cycle PCR program was executed on a Tpersonal Thermocycler (Biometra, Göttingen, Germany): The 
closing lid of the device was heated to 105 °C for the full term of the reaction. Initially the sample was heated to 
94 °C for 5 minutes to completely separate the template DNA strands. This was followed by 25 cycles of 96 °C 
for 30 seconds (strand separation), 55 °C (or lower with lower primer annealing temperatures, especially noted 
on primer Table 4) for 15 seconds and 60 °C for 4 minutes (elongation). Post reactive the PCR samples were 
purified using the PERFORMA® DTR Gel Filtration Cartridges (Edge Biosystems, Gaithersburg, MD; USA) 
with the recommended protocol. 5 µL eluate from the purification column was diluted with 15 µL distilled wa-
ter. The so diluted amplificates were electrophoretically separated and the fluorescence signal of the terminal 
ddNTPs was determined using an ABI Prism 310 or 3100 sequencer (Applied Biosystems). The resulting elec-
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tropherogram was analyzed using sequence analysis software ABI Prism 10 Collection in its version 3.4.1 (ABI 
Prism 310) and 3.7 (ABI Prism 3100). 
 
2.11 PCR primers 
PCR primers for direct sequencing and PCR amplification DNA were ordered in lyophilized state from 
Microsynth, Belgach, Switzerland and stored at -20 °C.  
Oligonucleotide properties were calculated using Oligo Calculator, version 3.07 (Research Computing, 
Northwestern University Medical School, Chicago, IL, USA). This software also allowed excluding primers 
with self-complementarities and a built-in BLASTN query (see 2.15) allowed excluding primers with high prob-
ability of mispriming (i.e. several annealing sites).  
2.11.1 Basic melting temperature calculations 
The two standard approximation calculations were used to calculate approximate melting temperatures 
when selecting primers for PCR reactions. For sequences less than 14 nucleotides Formula 6 was applied: 
Formula 6. zC)+4(yG + xT)+(wA2=mT  
where w, x, y, z are the number of the bases A, T, G, C in the sequence, respectively. 
 
For sequences longer than 13 nucleotides, the equation used is Formula 7: 
Formula 7. 
zC+yG+xT+wA
16.4)-zC+41(yG+ 64.9      =mT  
Assumptions: 
Both equations assume that the annealing occurs under the standard conditions of 50 nM primer, 50 mM Na+, 
and pH 7.0. 
2.11.2 Salt adjusted melting temperature (Tm) calculations 
A variation on two standard approximation calculations was used: 
Formula 8. [Na+]log 16.6 + 
zC+yG+xT+wA
820 -  
zC+yG+xT+wA
zC)+(yG 41 + 100.5 10=mT  
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2.11.3 Comprehensive list of primers used in this study 
Table 4. PCR primers used in this study. 
Name 5’-3’ sequence Length Tm (°C)¶ GC-content (%) 
244* CCC ACT GCT GCC TCC CGT AG 20-mer 60 70 
259* TTT CAC GAA CAA CGC GAC AA 20-mer 50 45 
264* TGC ACA CAG GCC ACA AGG GA 20-mer 56 60 
271* CTT AAC ACA TCG AAG TCG AAC 21-mer 50 43 
285* GAG AGT TTG ATC CTG GCT CAG 21-mer 54 52 
aph5’ CGT TTC CCG TTG AAT ATG GCT C 22-mer 55 50 
aph3’ CTC CTT CAT TAC AGA AAC GG 20-mer 50 45 
ET1 AAG CGG TTG CCG CCG ACC GAC C  22-mer 64 73 
ET2 CTG GCT ATA TTC CTG GGC CCG G  22-mer 60 64 
ET3 GAG GCG ATC TGG CGG TTT GGG G  22-mer 62 68 
hyg_start TCG ACG ACG CGG GGG AC 19-mer 57 76 
hyg_stop TCG CAG CAG CGG GCT TCG 18-mer 57 72 
nRD18-flank.F GCG GTG CTG GCC TTT GTC A 19-mer 55 63 
nRD18-flank.R GCG GGC AAA GGC GAT GAC 18-mer 55 67 
P1 CCC AGT CAC GAC GTT GTA AAA C 22-mer 55 50 
P2 GCA GAC GTC CCC GAT CAA AG 20-mer 56 60 
P3 CAT CAA ATA AAA CGA AAG GCT CAG 24-mer 52 38 
RD2-flank.F CTC GAC CGC GAC GAT GTG C 19-mer 58 68 
RD2-flank.R CCT CGT TGT CAC CGC GTA TG 20-mer 56 60 
RD2-Rv1979-int.R ATC GGC ATC TAT GTC GGT GT 20-mer 52 50 
RD2-Rv1979.int.F TAT AGC TCT CGG CAG GTT CC 20-mer 54 55 
RD8-flank.F CTG GCA GCC GCT CAA GAC C 19-mer 58 68 
RD8-flank.R GGC TCG ACC GCG TTC AGA C 19-mer 58 68 
RD8-Rv0309.int.R GTA CTG CGG GAT TTG CAG GTT C 22-mer 57 55 
RD14-flankR GGG CTG GTT AGT GTC GAT TC 20-mer 54 55 
RD14-flankF TTG ATT CGC CAA CAA CTG AA 20-mer 48 40 
RD14-Rv1769.int.F GTG GAG CAC CTT GAC CTG AT 20-mer 54 55 
RD14-Rv1769.int.R CGT CGA ATA CGA GTC GAA CA 20-mer 52 50 
RDDenmark-flank.F CTA CAA AAG CAA CCG GAC GCA GTG 24-mer 59 54 
RDDenmark-flank.R GGC CAG CCG GAG AGC GAA ATC 21-mer 60 67 
RDFrappier-fl.F GAT TCT CGA GCC GTC AAC CAA CC  23-mer 59 57 
RDFrappier-fl.R CGA ACG CGC CGA ACA G  19-mer 51 69 
RDFrappier-Rv3495 ACG ACC CGA CGG ATC CTT TTA T  22-mer 55 50 
RDRussia-flank.F GGG CGT CGG GAA CCA GAT TG 20-mer 58 65 
RDRussia-flank.R CGC GAC CGC CGA TGA CAC 18-mer 57 72 
recA3_start CAT GCA TAT GAC GCA GAC CCC CGA TCG 27-mer 64 59 
recA3_stop GCA CTA GTG CCC GCG CCT GCT CTT C 25-mer 66 68 
recAPstI_for GAA CAG GCA CTC GAG ATC 18-mer 50 56 
recAPstI_rev CTA AGA CCT GCT TCA TTC C 19-mer 55 47 
recA_965_983 CCG ATC ACA AGG TGC TGA C 19-mer 60 58 
recA_599_618 TCG GAG TGA TGT TCG GGT CG 20-mer 63 60 
recA_1307_1326 CCG GTA TCT ACG GCA AGC TC 20-mer 63 60 
recA_1687_1705 GCG CTT ATC CAG GCG ATT C 19-mer 60 58 
recA_1972_1990 TCC GTG ATC CGA GAA GTG C 19-mer 60 58 
Rv3676_for GGC CAG CCC AAT CCG CAG TTT AG 23-mer 61 61 
Rv3676_rev CTG TGT CTG CTG GGC GTG AGG AAG 24-mer 63 63 
SP6** ATT TAG GTG ACA CTA TAG 18-mer 41 33 
T3** AAT TAA CCC TCA CTA AAG GG 20-mer 48 40 
T7** GTA ATA CGA CTC ACT ATA GGG C 22-mer 53 45 
¶ Calculated according to Formula 7 
* 16S rRNA primers (117) 
** vector primers 
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2.12 Plasmids 
2.12.1 Plasmids used in this study 
Table 5. Plasmids used in this study 
Name, Accession¶ Features (selectable/counterselectable Source or Reference 
 markers, size) 
pBluescript II KS(-), commonly pBS bla (ampicillinr), 2961 bps Stratagene, La Jolla, CA USA (122) 
X52329    
pMCS5 bla, 3081 bps  MoBiTec, Göttingen, Germany (123) 
pGEM®-7-Zf(+) bla, 2997 bps Promega, Madison, WI, USA 
X65310 
pUC4k bla, aph (kanamycinr), 3914 bps Calgene, David, CA, USA 
X06404 
pBR322 bla, tet (tetracyclinr), 4361 bps (124) 
J01749 
pEJ126 bla, recA, 17608 bps (61) 
pIJ903 bla, thio (thiostreptoner), hyg (125) 
pBS-recA, #819 bla, recA (anticlockwise), 8189 bps (5) 
pBS-recA, #820 bla, recA (anticlockwise, identical with #819) (5) 
pBS-recA::aph, #820 bla, recA::aph (clockwise), 8174 bps (5) 
pBS-recA::3xstop bla, recA::3xstop, 6956 bps this study 
pMCS5-hyg bla, hyg (hygromycinr), 4838 bps this study 
pMCS5-hyg(short) bla, hyg (short hyg cassette from PCR), 4417 bps this study 
pMV361-hyg hyg, 8694 bps  (103) 
pGEM7-hsp60-sacB bla, sacB (sucroses), 5494 bps Sven Hobbie, (126) 
pGEM7-hsp60-sacB-aph bla, aph, sacB, 6734 bps this study 
pGEM7-hsp60-sacB-aph-hyg bla, aph, hyg, sacB, 8066 bps this study 
pGEM7-hsp60-sacB-aph-hyg(short) bla, aph, hyg (short), sacB, 7986 bps this study 
pGEM7-recA::3xstop-hsp60-sacB-aph-hyg bla, aph, hyg, sacB, recA::3xtop, 12066 bps this study 
¶ GenBank/EMBL accession number (only where available) 
 
2.12.2 Construction of the M. bovis BCG ΔrecA::3xstop suicide plasmid 
The recA gene of M. tuberculosis was originally cloned and sequenced by Davis et al. in (62): A 13.2-
kb EcoRI recA fragment was cloned in the EcoRI site of pBR322 and the resulting vectors were termed pEJ126 
and pEJ127 (opposite orientation) respectively.  
For the generation of suicide vector pGEM7-hsp60-sacB-recA::3xstop-hyg-aph the following cloning 
steps were performed: A 5.2-kb ApaI fragment from plasmid pEJ126 (62) containing M. tuberculosis recA was 
subcloned into the PstI site of plasmid pBluescript-KSII(-) after blunting of both fragments with T4 polymerase, 
resulting in plasmid pBS-recA as described by Sander et al. (5).  
From pBS-recA a 1.3-kb internal PstI fragment (recA bps 504-1758 in protein residues 169-586) was 
replaced by a 22-mer triple translation stop insert with an internal MunI restriction site and PstI overhanging 
ends (Figure 17). This 22-mer was generated by annealing of dimeric oligonucleotide primers with 5’-
phosphorylated ends. Briefly: two dimeric 5’-phosphorylated oligonucleotides were ordered from Microsynth 
(Belgach, Switzerland) in a concentration of 100 µM each. The oligonucleotides were diluted in annealing buffer 
(10 mM Tris-HCl, ph 8.0; 50 mM NaCl; 1 mM EDTA) to a concentration of 10 µM. The two oligonucleotides 
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were mixed at equal volumes (resulting in a final concentration of 5 µM per oligonucleotide). The mixture was 
heated to 96 °C for 5 minutes in a PCR machine and cooled down to 25 °C over a period of 8 hours. The anneal-
ing product was diluted 1:10 and used for ligation. 
An hsp60-sacB construct in form of an EcoRV/BamHI fragment from plasmid pLO2 (127) was ligated 
to the BamHI/EcoRI site of pMV361 (103) to result in pMV361-hsp60-sacB, wherefrom an XbaI/XhoI fragment 
was ligated in the XbaI/SacI site of pBluescript-IIKS(-), to result in pBS-hsp60-sacB. The later plasmid was 
digested with ApaI and NheI and a 2514-bp fragment ligated into pGEM7-Zf(+) digested with XbaI and ApaI, 
thereby excising 17 bps from the multiple cloning site to result in pGEM7-hsp60-sacB (5494 bps), expressing 
sacB under the control of the mycobacterial hsp60 promoter. The plasmid pGEM7-hsp60-sacB (5494 bps) was 
obtained from Sven Hobbie (126). 
A 1.3-kb aph cassette isolated as a PstI fragment from plasmid pUC4K was ligated into the NsiI restric-
tion site of pGEM7-hsp60-sacB. Then we introduced a 1.3-kb hyg fragment (from pMCS5-hyg cut with 
Bpu1102I and Van91I, treated with T4 polymerase to create blunt ends) containing the hygromycin B resistance 
conferring hygromycin phosphokinase gene from S. hygroscopicus. Cutting pMCS5-hyg with Van91I removes 
the first 48 bps of the hyg gene promoter (128). The resulting plasmid pGEM7-hsp60-sacB-hyg-aph was cut with 
EcoRV and SpeI. A 4-kb recA::3xstop fragment from pBS-recA::3xstop (cut with EcoRV and SpeI) was intro-
duced to result in suicide vector pGEM7-recA::3xstop-hsp60-sacB-hyg-aph which was used for transformation 
of the BCG substrains mentioned above. 
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Figure 14. Cloning of plasmid pBluescript-recA as performed by Sander et al. (5) 
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Figure 15. Cloning of plasmid pGEM7-hsp60-sacB-aph. 
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Figure 16. Cloning of plasmid pGEM7-hsp60-sacB-hyg-aph (empty suicide vector). 
 
 
Figure 17. 22-bp triple translation stop insert with MunI restriction site and PstI overhanging ends. The synthetic insert contains a stop codon 
for every reading frame.  
 
MATERIAL AND METHODS 
 42 
 
pBS-KSII(-)-recA 
8189 bps 2000 
4000 
6000 
8000 
SpeI 683 
PstI 3029 
PstI 4284 
EcoRV 5941 
phage f1 MCS' 
Rv2735c/Mb2754c 
recX 
recA 
intein 
Rv2737A/Mb2757 
Rv2738c/Mb2758c 
'MCS 
pUC origin 
bla 
        
  PstI, 6934 bps  pGEM7-hsp60-sacB 
               1255 bps    + aph from pUC4k 
   + hyg from pMCS5-hyg 
  ligate 
 
 
 
pGEM7-hsp60-sacB-aph-hyg 
8067 bps 
 
2000 
4000 
6000 
8000 
EcoRV 46 
SpeI 76 
hsp60  
promoter 
sacB 
hyg 
aph 
oriC pUC19 
bla 
phage f1 
 
  EcoRV, SpeI, 4027 bps EcoRV, SpeI, 8039 bps 
 2929 bps vector backbone 28 bps frag. 
 
 
             
Figure 18. Cloning of suicide vector for knock-out generation pGEM7-recA::3xstop-hsp60-sacB-hyg-aph. 
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2.13 PCR for generation of short hyg cassette 
The standard laboratory hyg gene cassette from pIJ903 (125) has a size of 1.8 kbs which is undesirably 
long for a suicide knock-out vector. I intended to shorten the hygromycin B resistance cassette to an essential 
minimum by PCR amplification of hyg with its promoter and ligation of the product into a standard high copy 
vector. Hyg gene and promoter sequence was obtained through the NCBI database (129), accession numbers: 
M18863 (hyg promoter), X99315 (hyg gene) and verified with original literature (128). Two flanking primers 
were ordered (hyg_forward and hyg_reverse, see Table 4).  
The template has a GC-content of 77%, which is considerably high: Therefore I used a GC-RICH PCR 
System (Roche Diagnostics, Bale, Switzerland) for the amplification of the resistance cassette. The amplificate 
has a size of 1.3 kbs. The PCR product was cleaned by gel extraction and blunted with T4 polymerase. The blunt 
hyg cassette was inserted directly into pGEM7-hsp60-sacB-aph into the ApaI site. The resulting plasmid was 
sequenced with the following primers: P1, P2, P3, hyg_forward, hyg_reverse, aph5, and aph3. 
 
2.14 Protein methods 
2.14.1 Preparation of cell-free extracts 
For the determination of RecA expression after DNA damage induction with mitomycin C, BCG cell-
culture lysates were analysed by Western blot. Untreated and mitomycin-C-treated bacteria were harvested by 
centrifugation, washed with PBS buffer (pH 7.2) and resuspended in 300 µL PBS containing 0.5% protease 
inhibitor cocktail (Sigma). Bacteria were lysed in screw-cap tubes in a water immersion (ice-chilled) sonicator 
(Elma, Singen, Germany), using maximum duty-cycle during 1 h 20 min with a cooling intervall every 20 min. 
The crude lysate was clarified by spinning at 1 000 x g during 10 min.  
2.14.2 Protein quantification 
The total protein content of cell-free culture lysates was determined according to Bradford et al. (130). 
Quick Start Bradford Protein Assay (Bio-Rad) was used according to the instructions of the manufacturer. The 
Bradford dye assay is based on the equilibrium between three forms of Coomassie Blue G dye. Under acidic 
conditions, the dye is predominantly in the doubly protonated red cationic form (Amax= 470 nm). However, when 
the dye binds to protein, it is converted to a stable unprotonated blue form (Amax= 595 nm). 
500 µL of 1:500 diluted cell-free lysates were mixed with 500 µL of a working reagent consisting of 1 vol 
Coomassie Brilliant blue G dye stock (100 mg Coomassie Blue G in 50 mL methanol, 100 mL 85% H3PO4, 50 
mL H2O) and 4 vol H2O. Absorbance at 595 nm was measured and protein content of the samples was calculated 
by regression based on a standard curve obtained from a bovine serum albumine (BSA) standard dilution series.  
2.14.3 SDS gel electrophoresis 
Cell-free extracts corresponding to 50 µg total protein (quantification via Bradford assay) were used for SDS gel 
electrophoresis and subsequent Western blot analyses. Samples were mixed with one sample volume of sample 
buffer. A 13.3% polyacrylamide gel with a 4% stack gel was used to separate proteins. As a loading control, 
polyacrylamide gels were stained with Coomassie Blue G staining solution (Bio-Rad). 
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2.14.4 Western blot analysis 
Following SDS-PAGE in a 13.3% polyacrylamide, gel proteins were blotted to a PVDF membrane us-
ing semi-dry blotter (Bio-Rad) at constant current (0.3 A) for 30 min. Equal loading of proteins was confirmed 
by Coomassie staining of an identical gel the efficiency of blotting was controlled by Coomassie staining of the 
blotted gel. Membranes were incubated with mouse-antibodies raised against mycobacterial RecA (provided by 
E. O. Davis, 1:1000), and by parallel incubation with an additional primary mouse-antibody raised against a 
constitutively expressed mycobacterial protein (KatG, provided by S. T. Cole, 1:2500). Secondary antibody was 
a goat-anti-mouse HRP-conjugated antibody (GE Healthcare) used in 1:2500 dilution. After incubation with the 
antibodies, membranes were developed in ECL solution and used to expose photographic films. 
2.14.5 Buffers used for protein analyses 
Table 6. Protein analysis buffers 
Descriptor Composition 
PBS 220 mM NaCl, 150 mM Na2HPO4, 130 mM KH2PO4, pH 7.2 
SDS sample buffer 62.5 mM Tris-base, 25% glycerol (vol/vol), 2% SDS (weight/vol), 0.01% (weight/vol) bromphenol blue,  
  5% β-mercaptoethanol (vol/vol) 
Running buffer 25 mM Tris-base, 0.1% SDS, 1.44% glycine, pH 8.3 
TBST 50 mM Tris-base, 150 mM NaCl, adjusted to pH 7.5 with HCl, 0.05% Tween-20 
blocking solution TBST, 4% milk powder (weight/vol) 
ECL Immun-Star™ HRP, Luminol/Enhancer, peroxide buffer (1:1), all Bio-Rad 
2.15 Bioinformatics 
Bioinformatics were utilized for sequence analysis, alignments and similarity searches. 
2.15.1 Primary databanks 
1. The GenBank (131) in the USA is under the auspices of the National Centre for Biotechnol-
ogy (NCBI) and is an official sequence data bank which contains protein and nucleotide se-
quences from more than 55,000 different organisms. All sequences are identified or tagged 
with a unique accession number. A GenBank sequence is usually divided into two parts: the 
annotation, which contains precise and detailed information about the sequence and the se-
quence itself. The ENTREZ search machine is coupled with the GenBank and allows a spe-
cific search based on an accession number, organism, gene, protein or author. 
2. The EMBL nucleotide sequence database (132) is the European equivalent of the GenBank 
and utilizes the sequence retrieval system (SRS), a search machine similar to the ENTREZ 
for specialized searches of the database and many other databanks over the web interface. In 
addition to the text-based SRS and ENTREZ search engines described above, the basic logic 
alignment search tool (BLAST) was also extensively utilized. BLAST enables comparison of 
a particular sequence of interest with available databanks, leading to identification of similar 
sequences or relationships with previously described gene families.  
3. GenoList (118), a database dedicated to the analysis of the genomes of the tubercle bacilli at 
the Pasteur Institute was used for sequence comparisons. Its purpose is to collate and inte-
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grate various aspects of the genomic information from M. tuberculosis H37Rv (Tubercu-
List), M. africanum, M. bovis AF2122/97 (BoviList), M. bovis BCG Pasteur 1173P2, M. 
canetti, M. microti, and other species. TubercuList provides a complete dataset of DNA and 
protein sequences derived from the reference strain M. tuberculosis H37Rv, linked to the 
relevant annotations and functional assignments. The data contained in TubercuList origi-
nates mainly from the M. tuberculosis H37Rv genome sequencing project (133), supple-
mented with data and observations made by researchers at the Unité de Génétique Molécu-
laire Bactérienne at the Pasteur Institute. The data contained in BoviList originates from the 
M. bovis AF2122/97 genome sequencing project (120). The database is searchable using 
BLAST and FASTA software. 
4. M. smegmatis mc2 155 sequences were obtained through TIGR from the J. Craig Venter In-
situte (Rockville, MD, USA) which is a non-profit center dedicated to deciphering and ana-
lyzing genomes (134). 
 
The BLAST program (135), the TubercuList and BoviList databases were extensively used for se-
quence analysis and primer alignment studies. The BLASTN algorithm, which compares a nucleic acid query 
sequence with nucleic acid databanks directly, was used in this work. 
2.15.2 Sequence analysis and plasmid maps 
To align comparable DNA sequences, to identify point mutations DNA in files from automated DNA 
sequencing, and to perform sequence comparisons with published DNA sequences, sequences were assembled 
with SeqMan™ II DNA analysis software (DNASTAR, Madison, WI, USA). 
Plasmid maps were drawn and annotated using Clone Manager, version 6.0 (Scientific & Educational 
Software, Cary, NC, USA).  
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3 Results 
3.1 Generation of a recA targeting vector 
A targeting vector for generation of unmarked M. bovis BCG recA mutants was cloned by subsequent 
modular assembly of the inactivated recA allele (recA::3xstop), positive (aph, hyg), and negative (sacB) select-
able markers (Figs. 14, 15, 16, 17, 18)  
3.1.1 Vectors pBS-recA and pBS-recA::aph 
M. tuberculosis H37Rv recA gene and flanking DNA which have 100% sequence identity to M. bovis 
AF2122/97 segments was isolated from recombinant E. coli XL1-blue carrying pBS-KSII(-)-recA (#819, #820) 
and pBS-KSII(-)-recA::aph (#821). These vectors were cloning intermediates for generating marked recA dele-
tion mutant strains (5). Identity of the recombinant plasmid was verified by phenotypic characterization of E. 
coli strains with respect to the resistance markers conferred by the vector backbone, restriction enzyme digestion 
and sequencing of plasmids. The plasmid containing E. coli strains were cultured on LB media with ampicillin 
and kanamycin which revealed ampicillin resistance for plasmids pBS-KSII(-)-recA (#819, 820) and for pBS-
recA-aph (#821). For pBS-KSII(-)-recA::aph kanamycin resistance was noted. The plasmids were prepared on 
midi scale and 1 µg supercoiled DNA of vectors #819 and #821 was digested with restriction endonucleases 
EcoRV, PstI, and SpeI and fragments were separated by agarose gel electrophoresis (Figure 19).  
 
Figure 19. Gel electrophoresis (1% agarose gel, 5 Vcm-1, 1 h 20 min, ethidium bromide stained) with restriction analysis of vectors pBS-
recA (#819) and pBS-recA::aph (#821). The undigested supercoiled vectors run at 6 kbs. SpeI and EcoRV alone linearize both vectors, 
resulting in one fragment of > 8 kbs (besides a fragment of the same size as undigested vectors), both enzymes in a double digestion led to 
two fragments at approximately 6 kbs and 3 kbs for each vector. Digestion with PstI results in two fragments at approximately 1.2 kbs and 7 
kbs. 
The design of the multiple cloning site (MCS) of the used skeleton vector pBluescript allows sequenc-
ing over the multiple cloning site with primers T3 and T7. The obtained sequences revealed that the recA insert 
had the same reading direction as the bla ampicillin resistance cassette in vectors pBS-recA (#819 and #820) and 
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reverse direction in pBS-recA::aph (#821); all constructs exhibited the published wild-type recA flanking se-
quences of M. tuberculosis H37Rv and M. bovis AF2122/97. Primers recA_PstI_for and recA_PstI_rev were 
designed to sequence a 1.2-kb internal PstI fragment. In #819 and #820 this PstI fragment presented with the 
same sequence as in the published recA of M. tuberculosis H37Rv and M. bovis AF2122/97, in #821 the PstI 
fragment was replaced by an aph kanamycin resistance cassette originating from pUC4K. The aph gene had the 
same reading direction as the interrupted recA gene. To compute a complete vector map with sequence, the vec-
tor sequence of pBluescript-KSII(-) was obtained from GenBank (accession number X52329) and assembled 
with the insert sequence from direct sequencing, TubercuList queries on the H37Rv genome, and pUC4K aph 
sequence (GenBank accession number X06404). Vectors #819 and #820 have an identical sequence and the 
same size of 8189 bps (by computation analysis). #821 has a computed size of 8174 bps. Vector pBS-recA 
(#819, Figure 18) was used for further cloning in this study: After digestion of pBS-recA with PstI and gel elec-
trophoresis the 7-kb fragment was excised from gel and 5’-dephosphorylated. It was ligated to an artificial 22 
bps oligonucleotide generated by annealing of two 5’-phosphrylated, complementary primers (Table 4, Figure 
17). The oligonucleotide contains three stop codons, one in each frame on the complementary strand, a MunI 
restriction recognition site and PstI overhanging ends. After ligation of the fragments and transformation into 
DH5α a total of 19 CFU were obtained (low transformation efficiency in comparison to > 2500 CFUs after 
transformation with 1 ng pUC4K for the same batch of electrocompetent cells). Plasmids were harvested from 6 
clones, DNA was digested with MunI and SpeI and analyzed by agarose gel electrophoresis (Figure 20). Se-
quencing with primers recA_PstI_for and recA_PstI_rev was performed. 
 
 
Figure 20. 1% agarose gel, ethidium bromide stained. Plasmids isolated from DH5α after transformation with the ligation product pBS-
recA::PstI and triple translation stop insert. The insert contains a MunI restriction site which is not present in the vector. Lanes marked with c 
contain undigested plasmid preparation whereas d marked lanes MunI/SpeI digested plasmids. The numbers represent the clone numbers. 
Clones 1, 2, 4, and 6 show the expected restriction pattern with a 2.3 kbs and 4.6 kbs fragment.  
 
Sequencing revealed the presence of one to four inserted oligonucleotides in the four clones (Figure 21). 
The orientation of the oligonucleotides was random, as expected. Clone 2 exhibited the desired sequence, i.e. a 
deleted recA allele and a single oligonucleotide with the correct orientation, i.e. the stop codon of the 3x transla-
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tion stop insert is in frame with the reading frame of recA (Figure 22). The plasmid was named pBS-
recA::3xstop (Figure 18). 
 
Figure 21. Sequencing results of clones 1, 2, 4, and 6 from the ligation experiment pBS-rec::PstI + 3x translation stop insert. Clone 2 exhib-
its the desired sequence. 
 
 
Figure 22. Sequence electropherogram of pBS-recA::3xstop, cl. 2 sequenced with primer recA_PstI_rev with amino acid translation (num-
bers counting from Met1, recA initiation, reading direction is reverse, corresponding to genomic orientation of recA). 
 
3.1.2 Vector pGEM7-recA::3xstop-hsp60-sacB-hyg-aph 
E. coli XL1-blue were transformed with 2 ng of pGEM7-hsp60-sacB from frozen stock plasmid DNA 
solution, a midi scale plasmid preparation was performed, and the vector was characterised by restriction endo-
nuclease analyses and sequencing. The vector was initially generated by Sven Hobbie (126). The MCS of this 
vector carries the mycobacterial groEL2 (hsp60) promoter from M. bovis and further downstream the counterse-
lectable marker gene sacB from B. subtilis. A vector map including sequence was constructed by sequencing of 
essential parts of the vector with T7 and SP6 primer and computational assembling with the vector pGEM®-7-
Zf(+) sequence and annotations from GenBank (accession number X65310, Figure 15). Comparison of the se-
quences of the groEL2 promoter (accession number BX248335) and sacB gene (accession number Z99121) from 
sequencing to the published sequences in GenBank by BLASTN software confirmed identity with the sequence 
deposited in the database.  
A PstI excised kanamycin resistance cassette (aph; 1.2 kbs) from pUC4K was introduced downstream 
of sacB into the NsiI restriction site of vector pGEM7-hsp60-sacB to result in plasmid pGEM7-hsp60-sacB-aph 
(Figure 23A). The resistance cassette ideally should be integrated in the same reading direction as sacB to avoid 
interference of transcription as indicated in plasmid map pGEM7-hsp60-sacB-aph(+). Restriction analysis of the 
new construct with SmaI showed, that aph integrated stochastically in both directions as expected. Sequencing of 
three clones with primers aph3’, aph5’, and SP6 followed, confirmed the outlined restriction maps, and showed 
absence of mutations in the aph gene. Plasmid pGEM7-hsp60-sacB-aph(+) was used for further subcloning. 
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Figure 23. Restriction maps (A) and restriction digestion with SmaI (B) of pGEM7-hsp60-sacB-aph(+) and (-). After transformation plas-
mids from 10 clones were prepared and digested with SmaI (d, digested) and compared to undigested vector (c, control). The aph gene in 
clones 6 and 7 has the same orientation as sacB; in clones 8 to 10 reverse orientation can be noted.  
 
To generate pGEM7-hsp60-hyg-aph, a hygromycin B resistance conferring cassette (1.3 kbs) was pre-
pared from vector pMCS5-hyg with Bgl1102 and Van91I and subsequent blunting with T4 polymerase. To cut 
pMCS5-hyg with Van91I the vector had to be transformed in the dcm- strain DH5α Δdcm in order to allow nor-
mal function of the Van91I restriction endonuclease since this enzyme is Dcm-methylation sensitive. The vector 
pMCS5-hyg was generated by cloning of a standard Streptomyces hygroscopicus hyg cassette from pMV361-hyg 
into the multiple cloning site of pMCS5 (Martin Bosshard, unpublished). A vector map (Figure 17) was estab-
lished using the published pMCS5 sequence (123) and direct sequencing of the insert region of a plasmid prepa-
ration using T7, SP6, hyg_start, and hyg_stop primers. The sequencing showed a single base pair insertional 
mutation in the hyg promoter with respect to the published sequence of the hyg promoter (GenBank accession 
number M18863), which was present in the other laboratory held hyg vectors too (in originating pMV361-hyg as 
well as pBS-hyg derivate). To investigate normal function and hyg expression in E. coli a minimal inhibitory 
concentration (MIC) assay of four clones of DH5α cells containing pMCS5-hyg was performed: In all clones an 
MIC of 125 µg mL-1 hygromycin B was determined, confirming a hyg resistant phenotype (resistance level of 
non-transformant strain was 31.25 µg mL-1).  
In a subsequent cloning experiment vector pGEM7-hsp60-sacB-aph(+) was linearized with SacI, 
blunted with T4 polymerase, 5’-dephsophroylated, and a Bgl1102I/Van91I 1.3-kb hyg fragment originating from 
pMCS5-hyg was ligated into the vector to result in pGEM7-hsp60-sacB-hyg-aph. After transformation and selec-
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tion on LB-Hyg plates the orientation of the hyg gene in the newly generated pGEM7-hsp60-sacB-hyg-aph was 
uncovered by restriction digestion with SacI and SpeI. The hyg gene had the same orientation as the sacB gene in 
13 out of 16 clones analyzed, in 1 clone reverse orientation was noted, the remaining 2 clones showed inconclu-
sive restriction patterns. A computed vector map (Figure 25A) was confirmed by direct sequencing of clone 1 
(number as in Figure 24) with aph5’ and P3 primer. This plasmid was used for further subcloning.  
 
Figure 24. 1% agarose gel, ethidium bromide stained. Result of the ligation of pGEM7-hsp60-sacB-aph and hyg gene from pMCS5-hyg. The 
isolated plasmid (c, control, undigested) was analyzed in restriction digestion with SacI and SpeI (d, digested) resulting in fragments of 2811 
bps and 5255 bps for clockwise and 3545 bps and 4521 bps for anticlockwise orientation of the hyg insert.  
 
Based on pGEM7-hsp60-sacB-hyg-aph (Figure 25, panel A) the final suicide vector for the knock-out 
experiment was cloned: A 4027-bp fragment was prepared from pBS-recA::3xstop using EcoRV and SpeI. This 
insert was ligated to pGEM7-hsp60-sacB-hyg-aph, which was digested with the same enzymes and 5’-
dephosphorylated to result in pGEM7-recA::3xstop-hsp60-sacB-hyg-aph (Figure 25, panel B). 22 clones were 
analyzed in restriction digestion with EcoRV and SpeI. The obtained fragments corresponded to single insert 
integration in 20 clones. Two plasmids (cl. 7 and 8) out of those were sequenced with primers P1, P2, P3, SP6, 
recA_PstI_for, recA_PstI_rev, aph5’, and aph3’. They had the calculated sequence. The MIC of hygromycin B 
of recombinant E. coli DH5α containing the vector pGEM7-recA::3xstop-hsp60-sacB-hyg-aph (Figure 25, panel 
B), cl. 7 to be used for the knock-out experiment (see 3.3) was 250 µg mL-1 versus 31.25 µg mL-1 for the non-
transformant parental strain (the experiment was performed in triplicate). Plasmid pGEM7-recA::3xstop-hsp60-
sacB-hyg-aph has all the features required for generating unmarked recA deletion mutants. 
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Figure 25. (A) Empty suicide vector pGEM7-hsp60-sacB-hyg-aph for the generation of unmarked mutants in mycobacteria and (B) suicide 
plasmid for the generation of unmarked recA mutants. 
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Figure 26. 1% agarose gel, ethidium bromide stained. Ligation of pGEM7-hsp60-sacB-hyg-aph with 4 kb recA::3xstop fragment from pBS-
recA::3xstop. Control (c) versus digested (d) plasmids (EcoRV/SpeI), clones 7 to 12. Clone 7 was used for transformation of BCG vaccine 
strains. 
3.2 Choice and characterisation of Mycobacterium bovis BCG vaccine 
substrains 
3.2.1 Choice of M. bovis BCG substrains 
M. bovis BCG was propagated in several laboratories around the world. This resulted in a still ongoing 
in vitro evolution of different substrains. Alterations are mainly due to deletion and duplication of defined re-
gions (41). Single nucleotide polymorphisms (i.e. in crp, and sigK) have also been described (107, 116). The 
various genetic alterations – some presumably depending on RecA-mediated recombination - affect the anti-
genic, protective, and metabolic properties of BCG. The selection of BCG substrains based on criteria defined in 
section 1.3: History, passage number, morphological description and date of lyophilization could be obtained for 
all BCG used in this study. The selection comprises a representative for each branch of the phylogenetic tree 
displaying BCG in vitro evolution (Figure 27). 
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Figure 27. Genealogy of BCG vaccine substrains, modified from (41) with permission, copyright (2007) National Academy of Sciences, 
U.S.A., displaying the original virulent ancestor strain Mycobacterium bovis (isolated by Nocard in 1908) and the subsequent series of ge-
nomic alteration including deletions of regions of difference (RD), single nucleotide polymorphisms, and duplications of genomic regions. 
The recA alteration of BCG Russia described in section 3.4 (recA_D140*) is added to the scheme. Substrains that were used in this study are 
shaded in orange. 
3.2.2 Morphology and growth 
The BCG substrains all arrived in freeze-dried state in intact glass ampoules, which were welded in the 
case of BCG Frappier, Phipps, Pasteur, and Russia and closed with a rubber seal in the case of BCG Tice and 
Denmark. The number of CFU per vial was indicated only for BCG Tice (5 x 108). The visible amount of lyophi-
lizate varied greatly: BCG Denmark and Russia ampoules contained very small amounts whereas the amount in 
the BCG Tice ampoule appeared the most. First of all the specific appearance and molecular features of the six 
substrains were confirmed. 
3.2.2.1 BCG Frappier (ATCC #35735) 
From a freeze-dried lot, BCG Frappier was cultured in Middlebrook 7H9 medium in two culture flasks 
with 10 fold different innocula. In both culture flasks turbidity of media was visible starting on the third culture 
day. On day seven 100 µL of the culture were streaked on solid 7H10 agar and incubated for 21 days. On the 
same occasion samples were preserved for staining with Ziehl-Neelsen and Auramine-Rhodamine. Microscopic 
inspection of the Ziehl-Neelsen preparation showed acid-fast rods in aggregates and single occurrence without 
contaminants. In Auramine-Rhodamine red fluorescent bacilli of approx 3.5 x 0.5 µm were notable (Figure 29). 
After the incubation period uniform culture morphology was noted and on the 21st day of culture a sin-
gle typical colony was inoculated in 7H9 again. After three weeks of culture 100 µL of liquid culture were trans-
ferred to a 7H10 plate, incubated for 21 days, and then photographed (Figure 28). Single colonies were white-
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yellowish with marked difference in size between 3 and 9 mm and confluent. The colonies appeared rough with 
high tendency to the formation fine wrinkling (rugosity) of 1 to 2 mm in height. 
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Figure 28. BCG Frappier on 7H10 after 21 days of culture (black bar equals 5 mm). 
 
Figure 29. Auramine-Rhodamine stained direct preparations from 7H9 culture of BCG Frappier (white line corresponds to 10 µm). 
 
10 µm 
5 mm 
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3.2.2.2 BCG Phipps (ATCC #35744) 
For this strain the same procedure was applied: Cells were revitalised in 7H9, microscopic examination 
was performed (with the same results), cells were cultured on solid medium, a single colony was transferred to 
7H9 and the liquid culture was transferred to 7H10 for macroscopic culture examination. Rugosity could be 
observed in macroscopic culture morphology (Figure 30), even though in diminuend extent compared to BCG 
Frappier (Figure 28). 
 
Figure 30. Culture of BCG Phipps on 7H10 after 21 days of incubation. 
5 mm 
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3.2.2.3 BCG Tice 
BCG Tice was cultured and examined as the other substrains mentioned previously. According to acid-
fast staining the culture was pure. Macroscopic culture evaluation again showed less rugosity than in BCG Frap-
pier.  
  
Figure 31. 7H10 culture of BCG Tice, photographed on the 21st day of incubation. 
3.2.2.4 BCG Pasteur 
BCG Pasteur was cultured and examined in the same way as the previous substrains. Microscopic ex-
amination was indifferent but macroscopic morphology showed a marked difference: There were no line-like 
rugous elevations but spike-like structures. 
  
Figure 32. 7H10 with culture of BCG Pasteur on 21st day of incubation. 
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3.2.2.5 BCG Denmark 1331 
The cultivation and documentation of BCG Denmark was handled identically as for the previous strains. 
BCG Denmark exhibited strong formation of rugous structures. Single colonies appeared drier than colonies of 
the other substrains and were harder to pick with a loop. 
 
Figure 33. BCG Denmark on 7H10 on 21st day of incubation. 
 
3.2.2.6 BCG Russia 
A remarkable growth lag in comparison to the other strains was noted for the initial culture from a ly-
ophilized batch in a glass ampoule, there was no visible growth until the 7th day of incubation. Even though the 
medium was inoculated with approximately 20 mg of dried bacteria visible growth was only observed at day 29. 
16S-RNA gene PCR and subsequent sequencing confirmed that the medium contained bacteria of the M. tuber-
culosis complex. The sequence of a 1040 bps amplificate, which was generated by application of a protocol 
described by Kirschner et al. (136) using primers #285 and #264 showed 100% sequence identity with an ampli-
ficate from BCG Pasteur. An additional 7H9 culture flask was inoculated with the content of another fresh am-
poule of BCG Russia. The second batch proved more viable bacteria exhibiting faster growth with visible turbid-
ity on the third day of incubation. Again microscopic examination was indifferent to the previously mentioned 
substrains. After 21 days of incubation on solid agar the colonies produced relative high elevations (> 2 mm) 
with undulating forms.  
5 mm 
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Figure 34. 7H10 culture of BCG Russia after 21 days of incubation. 
 
3.2.3 Molecular identification of BCG substrains 
3.2.3.1 Regions of difference 
DNA/DNA hybridization techniques, PCR analyses and sequencing have identified several regions of difference 
(RD) between M. tuberculosis and M. bovis BCG substrains (41, 43, 91, 107, 111, 113-115, 137-139). Some 
regions of difference are characteristic for all BCG strains (RD1), while others allow the identification of spe-
cific substrains. The regions of difference (RD) indicated in Table 2 were analyzed in specific PCR reactions. 
DNA samples were prepared from the first 7H9 culture of every substrain. M. tuberculosis H37Rv served as a 
positive control and its annotated sequence (118) served as a reference. 
 
Table 7. Comparative results of RD specification of the analyzed BCG substrains confirming results of Mostowy et al. (115). 
BCG substrain Deleted regions Number of RDs ORFs affected Base pairs deleted 
M. tuberculosis H37Rv none 0 0 0 
Frappier ATCC #35735 RD1, RD2, nRD18, RD8, RDFrappier 5 30 30866 
Phipps ATCC # 35744 RD1, RD2, nRD18 3 23 21793 
Tice RD1, RD2, nRD18 3 23 21793 
Pasteur 1173B-P2 RD1, RD2, nRD18, RD14 4 31 30866 
Denmark 1331 RD1, RD2, RDDenmark/Glaxo 3 22 20972 
Russia RD1, RDRussia 2 11 11061 
 
3.2.3.1.1 RD8 
RD8 is a signature sequence of BCG substrain Frappier comprising of a deletion of 3428 bp. Behr et al. describe 
that BCG Frappier has a deleted RD8 (43). They examined three isolates from the Institut Armand-Frappier 
(IAF), Laval, Canada, without documenting the lot that is preserved at the ATCC. The three reference vials from 
the former bacterial collection of the IAF were not available for this study. DNA from BCG substrains and M. 
5 mm 5 mm 
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tuberculosis H37Rv served as a template. A multiplex PCR with primers RD8-flank.F, RD8-flank.R, and RD8-
Rv0309.int.R generates either of two fragments of similiar size, i.e. 286 bps and 292 bps. The 286-bp fragment 
results from template amplification with primers RD8-flank.F and RD8-Rv03909.int.R, whereas the 292-bp 
fragment results from template amplification with primers RD8-flank.F and RD8-flank.R. These fragments can-
not be differentiated by agarose gel electrophoresis but may be sequenced. 
 
Figure 35. 2% agarose gel, ethidium bromide stained. PCR amplificates of multiprimer PCR over RD8. Amplificate length of 286 bps 
corresponds to present RD8 sequence. For an absent RD8 a 292-bp amplificate was expected. 
 
Fragments of a size of approximately 300 bps were obtained with both M. tuberculosis and M. bovis 
BCG (Figure 35). Sequencing using the RD8-flank.F primer in order to confirm the absence of M. tuberculosis 
homologue sequence at RD8 locus in BCG Frappier was necessary because a difference of 6 bps is not visible on 
a 2% agarose gel. Sequencing proofed that BCG Frappier ATCC #35735 has a deletion of 3428 bps at the RD8 
locus (Figure 36, lower panel); sequencing of the other products revealed the presence of the corresponding 
sequence (Figure 36 upper panel). 
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Figure 36 Excerpt from sequence electropherograms of RD8-PCR amplificates of M. tuberculosis H37Rv (identical with sequences of all 
BCG substrains except BCG Frappier) and M. bovis BCG Frappier with M. tuberculosis H37Rv enumeration (numbers according to Tuber-
cuList). 
3.2.3.1.2 nRD18 
nRD18, a deletion of 1547 bps, distinguishes BCG substrains Pasteur, Phipps, Frappier, and Tice from 
substrains Denmark, Russia, and M. tuberculosis H37Rv. Due to the small size of the deletion, presence and 
absence of this region can be demonstrated in a PCR assay containing only two flanking primers (nRD18-
flank.F; nRD18-flank.R). These primers amplify a fragment of 249 bps (deletion) and 1796 bps (no deletion). In 
concordance with the published literature the length of the amplificates demonstrate deletion in nRD18 in BCG 
Frappier, Phipps, Tice, and Pasteur. BCG Denmark and Russia showed the same amplificate length as M. tuber-
culosis H37Rv, indicating the same sequence for these strains at locus nRD18. 
 
Figure 37. 1% agarose gel, ethidium bromide stained demonstrating amplificates of nRD18 region. 
 
3.2.3.1.3 RD14 
RD14 is a hallmark of BCG Pasteur. RD14 may be analyzed in two separate PCR reactions, which 
should give complementary results with respect to a positive or negative amplification. A 518-bp PCR product in 
the reactions with primers RD14-flank.F and RD14-flank.R is indicative of a deletion, whereas a PCR amplifica-
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tion product with primers RD14-Rv1769.int.F and RD14-Rv1769.int.R is indicative of a M. tuberculosis like 
sequence. Out of six analysed substrains, only BCG Pasteur showed a deletion at RD14. The PCR products were 
analysed on two separate gels. As expected the PCR reaction with primers RD14-Rv1769.int.F and RD14-
Rv1769.int.R gave no product for the Pasteur strain, whereas a product was obtained with two primers flanking 
the deletion (Figure 38). 
 
Figure 38. 2% agarose gels, ethidium bromide stained. (A) shows PCR amplificates of the RD14 deletion site obtained with a flanking and 
an internal primer, B) shows the amplificate, which was obtained with two flanking primers. 
 
3.2.3.1.4 RDDenmark/Glaxo 
RDDenmark/Glaxo is a 726-bp deletion specific for BCG Denmark and a derivative substrain, BCG 
Glaxo. Presence or absence of this region was demonstrated in a PCR containing region-flanking primers 
RDDenmark-flank.F and RDDenmark-flank.R. These primers amplify a 234-bp fragment if the region is absent 
and a 960-bp fragment if the region is present. RDDenmark/Glaxo was deleted in BCG Denmark 1331, no other 
of the examined strains presented with this deletion (Figure 39).  
 
Figure 39. 1% agarose gel, ethidium bromide stained. Amplificates over RDDenmark/Glaxo. 
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3.2.3.1.5 RD2 
RD2 differentiates BCG Russia from all other BCG substrains and from M. tuberculosis H37Rv. RD2 
was investigated by a multiplex PCR using primers RD2-flank.D, RD2-flank.R, and RD2-Rv1979-int.R in an 
assay similar to the RD1 test developed by Talbot et al. (see 2.7.1.8). A deletion in RD2 results in a PCR product 
of 1043 bps, which is generated by the annealing of the two flanking primers. If the sequence at the site of RD2 
is like in M. tuberculosis H37Rv, an 1884-bp product results from amplification with primers RD2-flank.F and 
RD2-Rv1979-int.R. With the exception of BCG Russia and obviously M. tuberculosis H37Rv, RD2 was deleted 
in all BCG substrains. The respective PCR produced sharply delimitable fragments without unspecific amplifi-
cates. 
 
Figure 40. 1% agarose gel, ethidium bromide stained. RD2 PCR products. 
 
3.2.3.1.6 RDFrappier 
RDFrappier is a hallmark of BCG Frappier. An analogous multiplex PCR setup as for RD1 (see 2.7.1.8) 
was chosen. If RDFrappier is deleted, two flanking primers (RDFrappier-fl.F and RDFrappier-fl.R) produce a 
229-bp amplificate; otherwise the internally laying primer RDFrappier-Rv3495c-int.R can anneal thereby fa-
vouring a 177-bp amplificate together with primer RDFrappier-flank.F. The amplificates can be separated in 2% 
agarose gel. The fragment sizes are clearly distinguishable. RDFrappier was deleted in BCG Frappier only; no 
other strain displayed a PCR product indicative for this deletion. 
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Figure 41. 2% agarose gel, ethidium bromide stained. Amplificates of PCR over RDFrappier. 
3.2.3.1.7 RDRussia 
Besides RD1, RDRussia is the only described region of difference in the genome of BCG Russia. 
RDRussia separates BCG Russia from other BCG substrains and M. tuberculosis H37Rv. The underlying dele-
tion has a lenght of 1603 bps. A PCR with two primers flanking RDRussia (RDRussia-flank.F and RD-Russia-
flank.R) was used to investigate RDRussia. The PCR produces a 1956-bp amplificate in H37Rv and BCG sub-
strains with intact RDRussia. If RDRussia is deleted, a 355-bp product results. Unfortunately the PCR over 
RDRussia produced unspecific amplificates and optimisation of the reaction was tried with variation of [Mg2+], 
annealing temperature, DNA strand dissolving agents (DMSO), and different polymerase blends. No measure 
led to the elimination of unspecific bands. Figure 42 shows that the expected fragment of approx 2 kbs for a 
present RDRussia was demonstrably there in all substrains but BCG Russia which had a distinct fragment of 
about 350 bps instead. Because a band of similar lenght was present in the PCR product featuring M. tuberculo-
sis H37Rv template too, the 2-kb amplificates of M. tuberculosis and BCG Denmark were excised from agarose 
gel and sequenced using primers RDRussia-flank.F and RDRussia-flank.R. The approximate 350-bp fragments 
from PCR of M. tuberculosis and BCG Russia were prepared and sequenced too. Sequencing demonstrated, that 
both analysed 2-kb fragments (BCG Denmark and H37Rv) have a 100% identical sequence (same sequence as 
annotated M. tuberculosis H37Rv at the RDRussia site). The sequence of the 355-bp fragment obtained from 
BCG Russia corresponds to a sequence with a deletion in RDRussia. A BLAST search reveals that the 350-bp 
fragment obtained from M. tuberculosis H37Rv corresponds to a repetitive element of PE-PGRS genes present 
in M. tuberculosis complex namely Rv0980c (PE_PGRS18). The fact, that the chosen primers allow amplifica-
tion and sequencing of an Rv0980c fragment, demonstrates the primers tendency towards mispriming. This is 
due to a high-degree homology of the respective priming sites (sequence flanking RDRussia and sequence 
within Rv0980c). 
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Figure 42. 1% agarose gel, ethidium bromide stained. PCR amplificates over RDRussia. 
 
Figure 43. Multiple sequence alignment of sequences derived from RDRussia-PCR using primers RDRussia-flank.F and RDRussia-flank.R. 
(A) is the sequence that was obtained from a 2-kbs amplificate using M. tuberculosis H37Rv DNA as a template. (B) is the sequence of the 
M. bovis BCG Denmark 2-kb amplificate. (C) is the sequence of the BCG Russia 350-bp amplificate using RDRussia-flank.F as forward 
sequencing primer; (D) is the reverse complement sequence of the same fragment using RDRussia-flank.R as reverse sequencing primer. (A) 
and (B) have the same sequence as M. tuberculosis H37Rv at the RDRussia site. In BCG Russia RDRussia is deleted (marked by -). 
3.2.3.1.8 RD1 
RD1 is deleted in all BCG substrains. This is the single most important region of difference that sepa-
rates attenuated BCG from M. bovis wild-type and from M. tuberculosis. RD1 encodes for parts of the ESAT-6 
system, which is an important contributor to the virulence of M. tuberculosis complex. The extended RD1 region 
encodes for a dedicated secretion system ESX-1 (assures export of the ESAT-6 protein and its partner, the 10-
kDa culture filtrate protein CFP-10) (140). Since the tragical Lübeck incident (35), where 77 of 251 infants died 
after they were vaccinated with a BCG vaccine batch contaminated with M. tuberculosis, all studies cultivating 
BCG vaccines should assure, that only non-virulent BCG is present in the culture media. Therefore a multiplex 
PCR was developed by Talbot et al. (119). They developed a diagnostically evaluated multiplex PCR applying 
three primers: ET1 and ET3 flank RD1, whereas ET2 anneals within RD1 (see Figure 11). In case RD1 is delete 
ET1 and ET3 amplify a 200-bp fragment, otherwise ET1 and ET3 produce a 150-bp fragment indicating that 
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RD1 sequence is present. The multiplex PCR method for detection of the RD1 deletion was shown to be highly 
sensitive and specific for the detection of BCG. The multiprimer assay for RD1 showed that all preparations 
from BCG substrains had an absent RD1, which excluded contamination of all vaccine strain preparations with 
M. bovis wild-type or even M. tuberculosis DNA. 
 
Figure 44. 2% agarose gel, ethidium bromide stained. Amplificates of RD1 PCR reaction. 
 
3.2.3.2 Mb3700/Rv3676 (cAMP receptor protein, CRP) 
The M. tuberculosis Rv3676 encodes for a cyclic AMP (cAMP) receptor-like protein (CRPMt), a global 
transcription regulator belonging to the CPR/FNR family, and may play an important role during tuberculosis 
infection. In general this regulator family controls the expression of many genes in the metabolism of carbons, 
nitrogen, sulphur, aerobic respiration, denitrification, nitrogen fixation, aromatic acid degradation, bacterial 
luminescence, and hemolysin synthesis. The CRPMt ortholog in Mycobacterium bovis BCG, CRPBCG, is dysfunc-
tional in an E. coli CRP competition assay and has been proposed as a potential contributor to M. bovis BCG's 
attenuation (141). Many transcriptional regulators form oligomers when bound to DNA. The CRP protein of M. 
tuberculosis recognizes a CRP-like palindromic sequence, suggesting that it also functions as a dimer consisting 
of two identical proteins. The N-terminal domain of the CRP protein contains a cAMP-binding site and the C-
terminal domain contains a helix-turn-helix (HTH) DNA-binding motif. Malltow et al. published that the gene 
products of Rv3676 (M. tuberculosis H37Rv) and Mb3700 (M. bovis BCG) exhibited different two dimensional 
electrophoretic mobility (142), Spreadbury et al. found specific point mutations in the Mb3700 gene allowing to 
differentiate BCG substrains (116). To further assure the identity of the substrains that were used in this study, 
the Mb3700 locus was amplified and sequenced. Characteristic point mutations were confirmed. The findings 
were consistent with the published literature: All BCG strains included in this study have a point mutation in 
comparison to M. tuberculosis and M. bovis affecting the first helix of the DNA-binding HTN motif. 
Guanosine532 is mutated to an Adenosine, resulting in a Glu178Lys replacement. There is a second point mutation, 
which is present in “younger” BCG substrains only. Thymidine140 is mutated to cytosine which results in amino 
acid change Leu47Pro. This mutation affects the cNMP-binding site of the CRP protein. Leu47 is usually con-
served in homologous proteins, even in E. coli CRP (Table 8). Of the BCG strains in this study all but BCG 
Russia have the T140 → C point mutation. There was an additional silent point mutation in thymidine205 which is 
changed to cytosine in all BCG vaccine strains.  
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Table 8. Mutation of Glu178 in HTH motif, which is present in all BCG strains examined, comparative chart. Spreadbury et al. (116) have not 
analyzed strains in bold letters so far. Percentage of amino acid identity is indicated with reference to M. tuberculosis H37Rv. 
Strain Ident. (%) AA# AA Sequence 
M. tuberculosis H37Rv 100 176 TQEEIAQLVGASRETVNKALADF 
M. bovis AF2122/97 100 176 ..E.................... 
BCG Frappier/Phipps/Tice/Pasteur/Denmark/Russia  99 176 ..K.................... 
M. leprae   96 176 ..E.................... 
M. avium  96 176 ..E.................... 
M. marinum  95 176 ..E.................... 
M. smegmatis MC2 155  97 176 ..E.................... 
C. glutamicum  79 179 ..E..................T. 
C. diphteriae  78 179 ..E..................T. 
S. coelicolor  54 176 ..E.................... 
E. coli   32 168 .RQ..G.I..C.....GRI.KML 
              Helix  Turn   Helix 
 
Table 9. Comparative chart displaying the mutation Leu47 which marks genealogically younger BCG substrains 
Strain Ident. (%) AA# AA Sequence 
M. tuberculosis H37Rv 100 25 QLQPVDFPRGHTVFAEGEPGDRLYIIIS 
M. bovis AF2122/97 100 25 ......................L..... 
BCG Russia  99 25 ......................L..... 
BCG Frappier/Phipps/Tice/Pasteur/Denmark  99 25 ......................P..... 
M. leprae   96 25 ..............T.......L...V. 
M. avium  96 25 ......................L...V. 
M. marinum  95 25 ......................L...VA 
M. smegmatis MC2 155  97 25 ......................L..... 
C. glutamicum  79 28 DMET.R....A.I.D.......L...T. 
C. diphteriae  78 28 D.ES.R....A.I.D.......L...T. 
S. coelicolor  54 25 SMSE.TLA..D.L.H..D....L.VVTE 
E. coli   32 17 HCHIHKY.SKSTLIHQGEKAETL.Y.VK 
 
In summary, molecular investigations of RD8, nRD18, RD14, RDDenmark/Glaxo, RDFrappier, 
RDRussia, RD1, and crp (Rv3676) confirmed identity of the BCG substrains. 
 
3.3 Generation of M. bovis BCG recA mutants 
Following M. bovis BCG substrain characterisation generation of recA knock-out mutants was at-
tempted. A total of 11 lots of electrocompetent cells were prepared for transformation experiments. With the 
exception of BCG Pasteur two different lots of the same substrain were transformed with the suicide knock-out 
generation plasmid pGEM7-recA::3xstop-hsp60-sacB-hyg-aph (Figure 25, panel B). Due to yield variations in 
the preparation procedure of electrocompetent BCG a control to determine the number of bacteria that are spon-
taneously resistant to hygromycin B or kanamycin could not be included in every transformation experiment. In 
case of low yield, suicide vector transformation had priority, as the primary intention of this study was to gener-
ate recA deficient mutants. A total of 49 batches of electrocompetent BCG cells were electroporated. 
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3.3.1 Transformation efficiencies in the different BCG substrains 
Suicide vectors integrate with a very low frequency. Therefore the bacteria’s competency to take up 
DNA is of critical importance. To measure transformation efficiency 1 µg of an integrative plasmid with a cas-
sette conferring resistance to hygromycin and kanamycin was used (pMV361-hyg). Plasmid pMV361-hyg carries 
an integrase (int) and an attachment site (attP) of mycobacteriophage L5 (103). Integration of plasmid pMV361-
hyg is based on site-specific recombination between plasmid encoded attP and bacterial attB site. The attP and 
attB sites share a 43-bps core region of identical sequence that overlaps the 3’ end of a tRNAGly gene of myco-
bacteria such that the integrity of the tRNA gene is maintained following prophage formation (143). Site-specific 
recombination is several orders of magnitude more efficient than homologous recombination of suicide vectors. 
The assessment of transformation efficiency was performed as outlined in chapter 2.4.2. The first transformation 
experiments with BCG Frappier, Phipps and Tice showed that the method provided only a raw estimate of the 
transformation efficiency if the number of CFU per plate exceeded 4000 due to CFU number estimation difficul-
ties. For further experiments the cultures of the control transformations were diluted in three tenfold steps. All 
dilutions were plated and transformation efficiency was calculated per diluted assay and as a mean value of the 
three logarithmic dilutions. Negative transformation control was performed by plating of cells that were electro-
porated without the addition of plasmid DNA. An equivalent of approximately 330 µL (after centrifugation of a 
diluted overnight culture) of the initial 400 µL transformational sample was plated on 7H10 media containing 
kanamycin or hygromycin to determine the background of spontaneous kanamycin resistant bacteria among the 
transformants. The effective number of CFU in the plated sample was determined. The cultures on hygromycin 
media have never grown spontaneously resistant BCG colonies whereas spontaneous kanamycin resistance could 
be noted in all BCG substrains. The number of spontaneous kanamycin resistant bacteria in a transformation 
sample varied between 1 and 300. This confirms observations by Pavelka et al. (144) who have never observed 
spontaneous resistance to hygromycin in the generation of a lysin auxotrophic mutants in BCG Pasteur and BCG 
Connaught neither. 
 
Figure 45. Transformation efficiencies (CFU per µg of integrative plasmid pMV361-hyg) in different substrains of BCG. Error bars indicate 
one standard deviation (where applicable). 
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Table 10. Comparison of transformation efficiencies (calculated as mean value of all interpretable transformation control cultures of the six 
substrains, in brackets number of interpretable samples on which the value bases on). n indicates the number of transformation experiments 
per strain, KanR/HygR gives the number of CFU that arose from plating of a negative transformation control sample on the respective antibi-
otics. 
BCG substrain n transformation efficiency per µg of pMV361-hyg spontaneously resistant 
  culture on 7H10-Kanamycin culture on 7H10-Hygromycin KanR HygR 
BCG Frappier 2 2.02·104 (1) 1.26·104 (1) 28 0 
BCG Phipps 2 1.92·104 (1) 3.11·104 (1) 300 0 
BCG Tice 2 not available¶ 1.20·104 (1) 40 0 
BCG Pasteur 1 1.95·105 ± 6.32·104 (3) 1.14·106 ± 4.81·105 (2) 1 0 
BCG Denmark 2 3.89·105 ± 4.64·105 (5) 1.92·106 ± 1.09·106 (4) 10 0 
BCG Russia 2 7.95·103 ± 6.20·103 (3) 9.09·105 ± 7.37·105 (2) 2 0 
 
¶ No reliable data available: No logarithmic dilutions of control culture were performed, platting of undiluted control assay resulted in bacte-
rial overgrowth of the Kanamycin plate (> 10000 CFU equaling a transformation efficiency of > 1·105 KanR CFU per µg of pMV361-hyg). 
 
3.3.2 Transformation efficiency with suicide recA targeting plasmid 
As described by Hinds et al. (102) an increase in the efficiency of recombinational integrations of al-
leles on suicide plasmids in the mycobacterial chromosome may be achieved by UV irradiation of the plasmids. 
For this study an assay to examine this previously established thesis was established. In four BCG substrains 
(Frappier, Phipps, Tice, and Pasteur) electrocompetent cells were transformed with untreated suicide knock-out 
vector and a sample of UV irradiated vector (1.5 µg plasmid for each experiment). Recombination efficiency 
was compared by counting of the HygR (and KanR in case of BCG Pasteur) CFU after transformation. 
 
Table 11. Results of vector UV irradiation experiments: Two different preparations (cls. 1 and 7) of suicide knock-out vectors were irradi-
ated with 100 mJcm-2 and electroporated in 400 µL competent BCG cell preparations. The electroporated cells were resuspended in 5 mL 
7H9 medium. Two different amounts of cells were plated. The contents of 1.0 mL and of 4.0 mL 7H9 medium were plated on solid media 
containing the mentioned antibiotics. No plating on Kanamycin media was carried out in BCG Frappier, Phipps, and Tice. 
BCG substrain Vector # Amount plated HygR colonies HygR colonies  KanR colonies KanR colonies 
  mL UV irradiated vector control (not irradiated) UV irradiated vector control (not irrad.) 
BCG Frappier 1 1.0 0 0  na na 
 1 4.0 0 30 
 7 1.0 1 0 
 7 4.0 50 0 
BCG Phipps 1 1.0 0 0  na na 
 1 4.0 0 30 
 7 1.0 1 0 
 7 4.0 50 0 
BCG Tice 1 1.0 0 3  na na 
 1 4.0 0 10 
 7 1.0 0 0 
 7 4.0 1 0 
BCG Pasteur 1 1.0 1 2  0 2 
 1 4.0 2 8  16 25 
 7 1.0 1 1  6 1 
 7 4.0 16 23  25 73 
BCG Denmark na na na na  na na 
BCG Russia na na na na  na na 
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3.3.3 Selection of transformants and identification of homologous recombi-
nants 
Prior to counterselection of transformants, these had to be differentiated form spontaneously resistant 
KanR/HygR bacteria. Therefore colonies growing on hygromycin containing selective media were amplified and 
analysed by PCR (see 3.4.1) and Southern blot analysis (3.4.2) after transformation with the suicide knock-out 
plasmid pGEM7-recA::3xstop-hsp60-sacB-hyg-aph. Advantageously the fast PCR screening may be performed 
from half a colony of one millimetre diameter (the rest may be streaked on a agar plate). It readily separates 
transformants from spontaneously HygR/KanR bacteria but it does not differentiate whether homologous or ille-
gitimate recombination events led to integration of the knock-out plasmid in the bacterial chromosome, which is 
most reliably determined by Southern blot analysis. In order to identify single-crossover transformants for the 
recA locus, only Southern blot analysis proved to be reliable due to occurrence of illegitimate recombinants 
(Table 12). 
Single-crossover transformants were identified in BCG Frappier, Phipps, Tice, Pasteur, and Denmark, 
but not in BCG Russia. 
 
Table 12. Analysis of recombinants in BCG substrains Pasteur, Frappier, Denmark, and Russia following transformation with recA targeting 
plasmid pGEM7-recA::3xstop-hsp60-sacB-hyg-aph. 
BCG substrain # HygR # analyzed transformants HygR 
  (Southern) HR IR with uncertain recA genotype 
Frappier 90 9 2 1 6 
Phipps 83 7 1 0 6 
Tice 20 7 1 2 4 
Pasteur 54 11 2 3 6 
Denmark 377 21 10 2 9 
Russia 72 23 0 16 7 
 
For counterselection single-crossover transformants were subcultured in liquid Middlebrook 7H9 and 
streaked on sucrose containing Middlebrook 7H10 agar in 10-fold dilution series. A precise calculation of the 
counterselective efficiency could not be established for the selection of allelic exchange mutants in M. bovis 
BCG using the sacB gene as counterselective marker due to throughput limitations in the subsequent screening 
of candidate allelic exchange mutant (PCR and Southern analysis). Media containing less than 10% sucrose 
proved inadequate for the selection of allelic exchange mutants; almost no difference in CFU counts could be 
seen as compared to controls. Therefore only 10% sucrose containing counterselective media were used. 
In such a manner recA knock-out mutants were isolated in BCG Frappier, Pasteur, and Denmark (Table 
13). In BCG Russia, illegitimate integration of the knock-out plasmid was observed in 16 out of 16 transfor-
mants analyzed by Southern blot (Figure 48). 
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Table 13. Isolates after counterselection (CS): Southern blot analysis results. cCS gives the number of clones that grew on counterselective 
plates., n gives the number of clones that were analysed by Southern blot after a recA deletion specific PCR; ni gives the count of interpret-
able results (equals 100%).  
BCG substrain Southern 
 n  ni knock-out 3’ sco  5’ sco  wild-type IR  no signal 
Frappier 7  6 50% (3/6) 33.3% (2/6) 0%  (0/6) 16.7%  (1/6) 0%  (0/6) 1/7 
Phipps 8  8 0%  (0/8) 0%  (0/8) 12.5% (1/8) 87.5%  (7/8) 0%  (0/8) 0/8 
Tice 36  23 0%  (0/23) 0%  (0/23) 0%  (0/23) 100%  (23/23) 0%  (0/23) 13/36 
Pasteur 16  15 20% (3/15) 0%  (0/15) 0%  (0/15) 75%  (12/15) 0%  (0/15) 1/16 
Denmark 12  10 50% (5/10) 0%  (0/10) 0%  (0/10) 40%  (4/10) 10%  (1/10) 2/12 
 
3.4 Characterisation of recA mutants 
Putative BCG mutants were analysed in different manners: i.e. PCR amplification at the site of deletion, 
Southern blot analysis of genomic DNA with respect to the induced mutation, and Western blot analysis after 
SOS-response induction. 
3.4.1 Specific PCR for recA locus 
A specific PCR was established to screen BCG transformants for a mutated recA allele. Primers lining 
within the recA gene, adjacent to the deletion site, were chosen. Primer recAPstI_forw and recAPstI_rev were 
used in the screening PCR. The amplification product from wild-type genomic DNA has a size of 1489 bps 
whereas the muted allele is significantly shorter with 274 bps. The two different fragments can be discerned 
easily by agarose gel electrophoresis. The template DNA was gathered by simple boiling preparation either from 
single BCG colonies or from liquid media grown cells (approximately 0.5 mL densely grown culture).  
The flaw of this PCR reaction is the inability to properly distinguish single crossover transformants 
from knock-out mutants. Because of preferential amplification of the short fragment over the long the presence 
of a 250-bp and absence of a 1.5-kb fragment does not proof allelic replacement; the screening test does not 
always produce two amplificates if the template is a single-crossover transformant (see Table 14). It is also sus-
ceptible to a false positive reaction: In the screening of BCG Phipps clones after counterselection 7/8 reactions 
produced 274 bps amplificates even though in Southern blot only 1 clone had a fragment indicative of the de-
leted recA allele. Therefore PCR positive knock-out candidates were subsequently analysed by Southern blot-
ting. 
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Figure 46. Ethidium bromide stained 1% agarosis gel electrophoresis (5 V cm-1, 1 hour 20 min) of PCR products (screening of a M. bovis 
BCG Denmark recA 5’ single crossover transformant [cl. 103] on 7H10 with 10 % sucrose). Lane 1 is the amplificate corresponding to wild-
type allele; lanes 2, 4, and 6 contain amplificates of recA knock-out mutants; lanes 3 and 5 contain two different amplificates originating 
from the parental single crossover transformant; lane 7 is the negative control (PCR without template). These findings were subsequently 
confirmed by Southern blot analysis. 
 
Table 14. Isolates after counterselection (CS): PCR screening results. cCS gives the number of colonies that grew on counterselective plates., 
n gives the number of clones that were analysed by a recA deletion specific PCR (see 3.4.1), ni is the number of interpretable PCR results 
(equals 100%). A PCR ampificate of 0.25 kb is indicative of a deleted recA; a 1.5 kb fragment is indicative of a wild-type recA.  
BCG substrain cCS PCR 
  n  ni 0.25 kb (del.) 1.5 kb (wt) not interpretable 
Frappier 300 33  22 95.5%  (21/22) 4.5%  (1/22) 11/33 
Phipps 9 8¶  7 100%  (7/7) 0%  (0/7) 1/8 
Tice 48 45¶  2 50%  (1/2) 50%  (1/2) 43/45 
Pasteur 16 16  3 100%  (3/3) 0%  (0/3) 13/16 
Denmark 12 12  12 75%  (9/12) 25%  (3/12) 0/12 
¶  One or several colonies could not be propagated from the counter-selective plate and was lost. 
 
3.4.2 Southern blot analysis 
Colonies raising on counterselective, 10% sucrose containing media from the different BCG substrains were 
plated on non-selective 7H10 agar dishes after transformation with the recA suicide knock-out plasmid pGEM7-
recA::3xstop-hsp60-sacB-hyg-aph, and identification of single-crossover transformants on hygromycin contain-
ing 7H10 agar. Genomic DNA was extracted and treated with SmaI restriction endonuclease. After hybridization 
with a NotI-NheI recA fragment (412 bps) as probe, the transformants could be allocated to five categories: Mu-
tants with wild-type allele of recA locus (1962 bps fragment), mutants with suggestive 5’ upstream integration of 
the suicide knock-out plasmid containing the inactivated recA gene (1962 bps and 9579 bps fragments), mutants 
with 3’ downstream integration of the plasmid with the mutated recA (4088 bps and 5634 bps fragments), mu-
tants with orthologous integration of the inactivated recA gene, i.e. recA knock-out mutants (5906 bps fragment), 
and mutants with illegitimate integration of the inactivated recA gene (1961 bps wild-type fragment and addi-
tional variable fragment). To differentiate putative 5’ single-crossover transformants from illegitimate recombi-
nants genomic DNA was digested with NotI and Southern blot analysis was performed with the same probe. In 
this analysis a wild-type strain is characterized by a 6635-bb fragment, a 5’ single-crossover transformant by an 
8499-bp and a 4800-bp fragment, a 3’ single-crossover transformant by a 6635-bp and 7266-kb fragment, and a 
knock-out strain by a 5402-bp fragment. 
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Figure 47. Schematic drawing of the BCG recA locus: the wild-type locus is shown along with the vector used for inactivation, 5’ and 3’ 
single-crossover transformant, knock-out mutant. SmaI sites () and the size of the hybridizing fragments are indicated.  
 
 
Figure 48. Southern blot analysis of the recA locus. (A) BCG Frappier (ATCC # 35735, CIP 105920). Lane 1, parental M. bovis BCG Frap-
pier; lane 2, single-crossover transformant obtained with plasmid pGEM7-recA::3xstop-hsp60-sacB-hyg-aph (3’ single-crossover); lanes 3-4, 
recA (silent) knockout mutants obtained after counterselection of a single-crossover transformant on medium containing 10% sucrose.  
(B) BCG Russia (ATCC # 35740), lanes 1-9 transformants obtained with plasmid pGEM7-recA::3xstop-hsp60-sacB-hyg-aph; lane 10, 
parental strain. Approximately 500 ng of genomic DNA was digested with SmaI and hybridized to a recA probe. This blot shows a virtually 
at random integration of the suicide knockout plasmid containing the inactivated recA gene in substrain Russia. The presence of a 2.0-kb 
fragment corresponding to the original recA and the presence of a second fragment of varying size indicates non-homologous illegitimate 
recombination. 
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3.5 BCG Russia is a natural recA mutant 
3.5.1 Genomic recA sequence 
BCG Russia integrated the recA suicide knock-out plasmid by illegitimate recombination in 16 of 16 
cases analyzed by Southern blot. This observation led to the suspicion, that this substrain might be defective in 
homologous recombination. Therefore, recA was amplified using primers recA_start and recA_stop and Pfu 
polymerase and sequenced as outlined in 2.10. A single insertional mutation 413 bps from recA start was found. 
The respective sequence was deposited with the GenBank database accession EU442641. The mutation leads to 
translational frameshift and truncation by a premature translational stop in the major central RecA domain (resi-
dues 31-269). The truncated RecA has a length of 139 instead of 790 amino acids and lacks the complete C-
terminal part of the protein including loops L1 (residues 156-165) and L2 (195-210) implicated in DNA binding 
(70). BCG Frappier, Denmark, and Pasteur recA were identical with the annotated reference sequence encoding 
a functional RecA. 
 
Figure 49. Comparative alignment of DNA sequencing electropherograms for M. bovis BCG Pasteur 1173P2 and BCG Russia displaying the 
inserational SNP (C414) in the recA gene of BCG Russia. Thereby Leu139 is changed to Ala, which is immediately followed by a premature 
stop codon (D140*, * instead of Asp). Nucleotide and amino acid counting starts at the recA initatiation codon. 
 
3.5.2 RecA expression at protein level after SOS response induction 
Bacteria respond to DNA-damage by coordinated expression of a multitude of genes involved in repair 
and control of cell division – the SOS response (145): SOS genes are negatively regulated by LexA respressor 
protein dimers, which are bound to a 20-bp LexA consensus site (SOS box) upstream of the regulated genes, 
such as recA/recX in M. bovis BCG and M. tuberculosis (see Figure 2). DNA damage with strand crosslinks 
results in blockage of DNA polymerase at replication forks; single stranded DNA (ssDNA) accumulates at these 
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sites. In an ATP-dependent fashion, RecA is bound to the ssDNA, forms hexameric filaments, and becomes 
activated. Activated RecA acts as a coprotease in the autocatalytic digestion of the LexA repressor. 
The SOS response was induced by addition of DNA-damaging agent mitomycin C (0.2 µg mL-1) to a 
BCG culture with an OD600 of 0.6 and incubated for additional 24 hours (80). Western blot analysis using a 
RecA antibody demonstrated induction of RecA in strain BCG Pasteur, and absence and failure of induction of 
RecA in BCG Russia (Figure 50). A BCG Pasteur recA mutant was used as a negative control. 
 
Figure 50. Western blot analysis of cell-free protein extract from different BCG preparations (with and without SOS response induction by 
mitomycin C; 50 µg protein per lane). Detection was carried out using a polyclonal mouse α-RecA antibody (1:1000), mature RecA protein 
has an approximate molecular weight of 38 kDa. A polyclonal mouse α-KatG antibody was used as loading control (1:2500); KatG protein 
has a molecular weight of 81 kDa. Bands migrating around 50 kDa are unspecific; secondary antibody was HRP-conjugated goat-anti-mouse 
antibody (1:2500). 
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4 Discussion 
4.1 General aspects of recA inactivation 
4.1.1 RecA function and supposed impact on genome evolution 
In many bacterial species RecA is a multifunctional and evolutionary conserved protein, that is involved 
in general recombination and DNA repair. It regulates expression of DNA repair proteins (SOS response) and is 
the central enzyme of homologous recombination. Besides point mutations, intramolecular homologous recom-
bination, supposedly contributes to genomic evolution in pathogenic mycobacteria due to lack of other evolu-
tionary possibilities because of the high specialization on their ecological niche within phagocytic cells that 
shield them from contact with other bacteria. Comparative genomics of mycobacteria indicates that recombina-
tion events are a major driving force of mycobacterial evolution. Many differences in strains of M. tuberculosis 
can be attributed to RecA-dependent genetic rearrangements (146, 147). There is extensive evidence for large-
scale rearrangements, duplications and deletions arising from homologous recombination events in M. leprae 
(148), M. tuberculosis (149) and M. bovis BCG (59). Half of the proteins present in the tubercle bacillus have 
arisen from gene duplication and adaptation events. Tandem duplications are generally caused by unequal cross-
over between homologous sequences or by recombination of short DNA homologies. Homologous recombina-
tion between similar sequences may invert or delete genes. Several deletions in M. tuberculosis H37Rv genome 
resulted from recombination between adjacent repeats of IS6110 elements (149, 150). Sometimes, the molecular 
mechanisms underlying alterations at particular loci remain obscure and subsequent alterations may mask initial 
events. E.g. tandem duplication DU2 in M. bovis BCG Pasteur arose from duplication of a 100-kb genomic seg-
ment that subsequently incurred an internal deletion of 64 kbs (59). In analogy to M. tuberculosis, recA inactiva-
tion in M. bovis BCG should shield the genome from further intramolecular rearrangements. The finding, that an 
inactivated recA coexists in a background of a highly conserved genome in M. bovis BCG Russia substantiates 
the herein proposed impact of RecA mediated events in BCG in vitro genome evolution (Fig. 26).  
4.1.2 Importance of RecA in interspecies gene exchange 
RecA inactivation could prevent uptake of virulence genes from the pathogenic M. tuberculosis com-
plex into the genome of the attenuated M. bovis BCG vaccine in case such mechanisms will be uncovered. In the 
generation of enterohaemorrhagic E. coli (EHEC) live vaccines, the authors denote recA deletion as an important 
safety measure to prevent recombination of virulence genes with the pathogenic strains (151). Whether RecA 
mediates interspecies horizontal gene transfer in mycobacteria has not been clearly demonstrated, while in Sal-
monella RecA-dependent recombination mediates genetic rearrangements resulting in increased genetic instabil-
ity (2).  
4.1.3 RecA dependent virulence and in vivo persistence 
For the construction of a live vaccine based on M. bovis BCG, the relevancy of RecA function with re-
gards to intraphagocytic persistence and thereon depending immunogenicity had to be assessed. RecA expres-
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sion in BCG Pasteur is only upregulated by 1.46 fold 2 hours after professional macrophage cell invasion and 
not elevated anymore after 24 hours of intracellular survival (152). Known virulence factors of M. tuberculosis 
are upregulated up to 4.5 fold after 2 hours in the same microarray analysis. It has been demonstrated in a mouse 
vaccination and infection model (31), that recA is not a persistence associated factor in BCG. In fact recA defi-
cient BCG survives in the host as long as parental BCG and has equal immunogenetic properites which has been 
demonstrated by an M. tuberculosis infection challenge (5). In contrast to BCG, for which recA dependence of 
virulence and thereon depending persistence in the host can be excluded, recA has been shown to act as a viru-
lence factor in different bacterial species in numerous reports: It promotes DNA repair mechanisms, which are 
essential for the intracellular survival of Salmonella thyphimurium (153, 154). In this species, RecA plays a 
crucial role in protecting the DNA form the phagocyte oxidative burst during intracellular survival: recA mutants 
were susceptible to killing by macrophages in vitro and were shown to be attenuated in a mouse infection model. 
In Campylobacter fetus inversion of surface layer protein (SLP) gene cassettes – a process, which is essential for 
host immune defense evasion – is RecA dependent (155). Immunoescape is facilitated by a mechanism of nested 
DNA rearrangements involving the inversion of either a single sapA promoter-containing element or more tan-
demly arrayed SLP-cassettes. Intragenic recombination within a single pilin gene or multiple, distinct, partial 
pilin gene copies (silent, storage loci) is accounted for the Pilin antigenetic diversity in Neisseria gonorroeae and 
changes in the pilation phase (on-off switch after passage through host epithelium) (156). In the plant pathogen 
Erwinia carotovora RecA has proteolytical activity and cleaves a gene repressor protein (RgdA, repressor of a 
pectin-lyase gene) involved in the degradation of plant cell wall constituents (157). Noteworthy for this study, 
recA inactivation does not alter measurable parameters of virulence in Campylobacter jejuni (158), Corynebac-
terium pseudotuberculosis (4), Brucella abortus (159, 160), and certain Vibrio cholerae strains (161). These 
findings underline, that recA is not necessarily needed for intracellular persistence in all pathogenic bacterial 
species. 
4.1.4 Probable compensatory mechanisms for recA inactivation 
In E. coli recA mutants it has been shown, that radA compensates for recA inactivation to some extent 
with respect to DNA repair and homologous recombination (162). Like RecA, RadA is highly conserved in bac-
teria; in archea it plays an important role in homologous recombination (163). The previously mentioned study 
by Sander et al. (5) exclude that radA homolgous gene Rv3585 (Mb3616) compensates for recA inactivation 
related DNA-repair deficits in BCG. This is assumed because recA mutants are sensitive to DNA-damaging 
agents to a comparable extent as recA mutants in other species. It is suggested that BCG vaccine strains have a 
non-redundant recA gene; its inactivation decreases homologous recombination events (31). 
 
4.2 BCG vaccine substrains 
The selection of BCG substrains for this study based on genomic analyses more than on description of 
the relative protective efficacy: It was my goal to include substrain for the whole width of BCG’s phylogenetic 
tree. A review of the published literature about BCG substrain’s protective efficacy based on meta-analysis of 
major field-trials does not conclusively recommend a single most protective BCG substrain (46). Therefore only 
a broad selection of existing BCG strains, that are still in use and commercially available can assure future us-
ability of the generated recombinant strains. 
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The identity of the BCG substrains included in this work was confirmed by a set of specific region of 
difference (RD) targeted PCR assays, and phenotypical observations (single colony aspect). The results confirm 
the identity of the substrains used. Even though this study’s strains have different provenience (in four of six 
cases) than the matching strains that had been analyzed in detail by Behr et al. (43), the distinct deletions were 
also present in the included strains. Targeted PCR assays do not allow the detection of novel regions of differ-
ence, therefore total genomic identity of this study’s strain selection in comparison the ATCC held reference 
strains remains to be affirmed.  
The RD1 multiprimer PCR assay, which allows discrimination of apathogenic BCG from pathogenic M. 
tubeculosis complex, is the only RD specific PCR assay with published primer sequences (119, 164). Mostowy 
et al. used Affimetrix GeneChipTM to identify absent RDs in different BCG strains. PCR with flanking primers 
was subsequently applied to identify the exact extent of detected RDs (115). For this study, new flanking primers 
had to be designed, as the primer sequences of the previously mentioned study were not accessible. 
In some BCG substrains, single nucleotide polymorphisms supposedly further attenuated different sub-
strains. The orthologs of M. tuberculosis H37Rv ORFs Rv3676 (crp), Rv0445c (sigK), and Rv0758 (phoR), have 
incurred inactivating mutations in younger BCG substrains (41, 116, 165). This study has added evidence to the 
findings of Spreadbury et al. that point mutation in the DNA- and cAMP-binding domain of crp (Rv2676) oc-
curred in a certain timeline affecting only younger BCG strains. BCG substrains (Frappier, Tice, and Phipps), 
that have not been analyzed for crp mutations previously, have the same mutations that affected other younger 
substrains like BCG Pasteur. The results of these sequencing analyses further assure the identity of the substrains 
used in this study. 
 
4.3 WHO vaccine production guidelines 
WHO vaccine production guidelines (104) were followed wherever possible. The procedures applied in 
this study allowed generating M. bovis BCG recA deficient mutants in a vaccine preproduction setting. The fea-
sibility of the herein demonstrated recA inactivating strategy under WHO guidelines for BCG vaccine produc-
tion thus should be possible. 
Lot numbers and passage counts were noted and the vials obtained were part of seed lot batches with 
the lowest passage numbers on the market in order to allow further preclinical studies with the generated mu-
tants.  
The mutant generated in BCG Pasteur, and Frappier are derived directly from primary seed lots. The 
mutant generated in BCG Denmark is based on a production lot with higher passage number. If a recA mutant of 
BCG Denmark shall be used for vaccination trials, generation of the mutant directly form a primary seed lot 
batch should be considered. The parental strains of the mutant strains represent a selection of BCG substrains 
that could be used in a study fully complying with WHO vaccine production guidelines.  
Central cornerstones in good laboratory practice have been followed; especially contamination with 
pathogenic M. tuberculosis complex is highly unlikely, as those have never been handled in the same laboratory. 
RD1 multiprimer PCR assay demonstrated absence of RD1 in all vaccine substrains before the experiments. 
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4.4 Generation of unmarked mutants in mycobacteria 
Considering further use as a live vaccine or antigen delivery system of the herein described recA mutant 
BCG strains a strategy to generate unmarked knock-out mutants was chosen. The already existing recA mutant in 
BCG Pasteur (31) carries a kanamycin resistance marker. Plasmids containing kanamycin resistance have been 
allowed for US Food and Drug Administration (FDA) approved products in the past but future allowance is 
uncertain (6). Currently, penicillin resistance genes are not allowed to be present in FDA approved live vaccines. 
Absence of antibiotic resistance leaves the full antibiotic spectrum to the therapist in case a vaccinee is immuno-
compromised (e.g. has an HIV-infection). 
The markerless BCG mutants were generated by application of an allelic replacement strategy as de-
fined by Pelicic and others (7). This strategy was successfully applied for the generation of several unmarked 
mutations in the slow growing M. tuberculosis or M. bovis BCG: lprG-Rv1410 operon (166), hbhA (Rv0475) 
(167), lysA (Rv1293) (144), ureC (Rv1850) (168), and erp (169). As suggested in parts of the literature (7, 83, 
168) a sucrose concentration of 10% had to be used in the counterselection process for BCG; in M. smegmatis a 
2% concentration is efficient. There are concerns that this unphysiological, high concentration could select for 
unwanted adaptional mutations in BCG, which would alter properties of the recombinant vaccine strains. In a 
circumventory assay, selection of mutants on 2% and 5% sucrose containing media was tried but with the suicide 
knock-out plasmid pGEM7-recA::3xstop-hsp60-sacB-hyg-aph, which was used for all recA knock-out experi-
ments, only persistence of integrated plasmid could be noted after counterselection on 2% or 5% sucrose. The 
conclusion could be that the employed mycobacterial hsp60 (groEL1 regulatory region) promoter that regulates 
sacB expression in my construct, does not yield to enough SacB production in order to introduce a lethal effect at 
2%/5% sucrose concentration. In the construction of a lysine auxotrophic mutant in BCG Pasteur and Connaught 
mentioned above Pavelka and Jacobs used 2% sucrose media for the counterslective process (144). Their suicide 
knock-out plasmid pYUB657 contained the same artificial hsp60-sacB fusion that was employed in this study. 
Interestingly, they found a certain frequency of Sucr Hygr isolates that had not undergone a second recombina-
tion event after counterselction on 2% sucrose. They suggested, that inactivation of the sacB gene had occurred 
by the action of mobile insertion elements (170). In this study a non-representative number of clones that were 
obtained after plating on 2 or 5% sucrose media, phenotypically Sucr Hygr isolates were analyzed for presence 
and nucleotide alterations of sacB. Thereby no insertional elements could be found in the sacB gene. Since only 
a few Sucr Hygr mutants that haven’t undergone a second recombination event could be isolated from 10% su-
crose media, sacB inactivation is not a major cause of failure of counterselection on low concentration sucrose 
plates. 
So far, a counterselection strategy employing the sacB gene is the best-documented way to generate markerless 
mutants in M. tuberculosis, M. bovis and M. smegmatis. The results of this study confirm pervious findings con-
cerning feasibility and efficiency of such a strategy.  
4.5 Concluding remarks and outlook 
Availability of recA mutants in three substrains of BCG is of interest for further development of novel 
M. tuberculosis vaccines. These mutants are deprived of the major recombination pathway and therefore have a 
more stable genome. This property is important when BCG is considered as antigen delivery system. The in-
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creased genetic stability is an advantage in the production of vaccine lots because it reduces the need to keep low 
passage numbers from primary seed lots. 
Comparative genome and transcriptome analyses indicate that BCG Russia is an ancient BCG strain 
most closely related to the original strain attenuated by Calmette and Guérin (41). The finding, that this ancient 
BCG substrain is a natural recA mutant, gave an important clue on probable mechanisms of in vitro genome 
evolution of BCG.  
Considering the tremendously long terms that have to be observed in clinical field trials and the good 
safety record of certain BCG substrains, development of novel tuberculosis vaccines should relay on improve-
ments and adoptions of BCG rather then on attenuation of virulent M. tuberculosis (18). Due to regulatory re-
quirements safety and potency assessments of live recombinant M. tuberculosis vaccines supposedly is more 
arduous: As long as safety and incapacity to revert to wild-type virulence of a recombinant M. tuberculosis vac-
cine candidate is not proven, production of test vaccine lots needs to be performed under biosafety level 3 condi-
tions. Challenges will be to find appropriate quality dedicated BL-3 facilities and to maintain batch to batch 
variations as low as possible (171). In the production of BCG or recombinant BCG existing facilities and proto-
cols can be used.  
The combination of improved recombinant BCG vaccine with an antigen boost system might prove 
more efficient than BCG vaccination alone in middle term (10). The increase in incidence of tuberculosis in 
economically poor regions can only be counterfeited by an affordable efficient vaccination. 
The herein presented recombinant BCG substrains and the natural recA mutant in BCG Russia might be 
a good starting point for the construction and evaluation of novel tuberculosis vaccines. 
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